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Hepatitis B virus X protein (HBx) is strongly implicated in hepatitis B virus-
associated hepatocellular carcinoma (HCC). One of the main mechanisms by which HBx 
contributes to neoplastic transformation is by functioning as a transcription co-factor that 
alters host cellular transcription regulation. HBx is known to interact with and modulate 
several key transcription factors that have been shown to be deregulated in various human 
cancers such as p53, E2F1 and CBP/p300, and the resulting gene expression aberrations 
are thought to upset the delicate balance of cellular homeostasis in favour of oncogenesis. 
However, the role of HBx in modulating cellular transcription factors and the underlying 
mechanisms(s) of this deregulation are poorly understood. 
 
In this thesis, we have examined the role of HBx in modulating transcription of the 
master regulator p53. This is of great interest since altered p53-mediated transcription by 
HBx consequentially deregulates p53 target genes that are involved in many critical 
cellular processes including cell cycle arrest, DNA repair, apoptosis and senescence. 
Although several isolated studies have shown that HBx modulates p53 transcription 
primarily by altering its sequence-specific DNA-binding selectivity, the findings have thus 
far been controversial. We therefore first examined global potentially functional p53-DNA 
binding alterations by HBx by integrating (i) p53 chromatin immunoprecipitation-on-chip 
that identified differential p53-DNA binding patterns, with (ii) expression profiling that 
identified differentially expressed genes in a HBx-expressing cell culture system. We 
found that HBx altered p53 DNA-binding characteristics in several ways: HBx enhanced, 
alleviated as well as induced a novel shift in p53-DNA binding, and that a subset of these 
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alterations was associated with deregulated expression of the corresponding genes. 
Interestingly, we did not find any patterns between each type of p53-DNA binding 
alteration (enhancement, abolishment or shift) and the corresponding gene deregulation 
(up-regulation or down-regulation), alluding to a more complex mode of transcription 
deregulation than previously proposed. 
 
To dissect this modulation of p53 sequence-specific DNA binding by the viral X 
protein, we further characterized a HBx-deregulated candidate from the global p53 ChIP-
on-chip and expression profiling studies - p53-regulated apoptosis-inducing protein 1 
(p53AIP1). We present strong evidence from detailed mutagenesis and promoter studies 
that HBx induced a novel shift in p53 binding from the promoter to intron 1 of the 
p53AIP1 regulatory region and that this directly resulted in a deregulated, increased 
expression of p53AIP1. Importantly, we also found significantly higher p53AIP1 
expression in HCC patients with high HBx protein levels, highlighting the relevance of 
our in vitro findings in hepatocarcinogenesis. We further show that increased p53AIP1 
expression has biologically functional consequences – that of mediating HBx-induced 
apoptosis. Having demonstrated the potentially detrimental consequences of p53 
transcription deregulation by the viral protein, we further investigated the mechanism(s) 
by which HBx modulated p53.  
 
Using bioinformatics analysis complemented with experimental validation studies, 
we demonstrate that the shift in p53 binding at the p53AIP1 regulatory region was linked 
to a mechanism by which HBx perturbs specific p53-associated co-regulatory modules. 
Essentially, HBx disrupted a transcriptionally repressive p53-YY1-GATA-1-HDAC1 
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complex at the p53AIP1 promoter, but instead favoured recruitment of p53 with the co-
activator Sp1 at the intron 1 region that further recruited the transcription co-activator 
PCAF in a transcriptionally stimulating complex. We show that by tipping the HDAC-
HAT balance, HBx induced a specific p53 Lys320 ‘acetylation switch’ that is in part 
responsible for altering p53 binding site selectivity and consequent p53AIP1 deregulation. 
Consistent with our finding that particular transcription co-factors are favourably recruited 
with p53 in the presence of HBx, we found that distinct transcription factor motifs - 
including that of Sp1 - were selectively co-enriched in the vicinity of the p53 binding sites 
in the presence of HBx from the global p53 ChIP study. Moreover, in agreement with our 
finding that HBx-induced acetylated p53 Lys320 preferentially bound to the more 
structurally conserved intron 1 consensus site of p53AIP1, analysis of the consensus sites 
bound by p53 in the presence of HBx from the global p53 ChIP study revealed a similar 
preference for more conserved p53 response elements. These universal findings provide 
support for our proposed model of deregulated p53-mediated transcription as a global 
mechanism of p53-regulated transcription by the viral X protein 
 
Collectively, we have demonstrated for the first time, a role for the viral X protein 
in upsetting the carefully orchestrated transcription regulation by the master regulator p53. 
Using p53AIP1 as a model, we showed that HBx perturbs the dynamic interplay of 
transcription co-factors and co-regulators as well as specific p53 post-translational 
modifications that are critically needed for proper cellular homeostasis. The work in this 
thesis has thus provided invaluable insights to the transcription co-factor role of HBx in 
contributing to hepatocarcinogenesis and provides important directions for future efforts 
in the field of HBx research. 
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Chapter 1 Introduction 
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Chapter 1 Introduction 
 
1.1 Hepatitis B virus associated hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third 
leading cause of cancer deaths with an estimated 500,000 HCC-related deaths annually (El-
Serag and Rudolph, 2007; Parkin et al., 2005). Its poor prognosis of less than a 3% 5-year 
survival rate is largely due to late symptom manifestation and unresponsiveness to treatment. 
At present, surgical resection and liver transplantation are still the most effective methods to 
treat the disease, but these options are only feasible in the minority of cases where the 
tumours are small and localized. Several risk factors are known to be associated with HCC. 
These include hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, aflatoxin 
b1 exposure and excessive alcohol intake. Of these risk factors, chronic HBV infection is 
most strongly associated with HCC, accounting for more than half of HCC cases worldwide 
and an estimated 80% in highly endemic areas such as Southeast Asia and sub-Saharan 
Africa. With approximately 350 million people chronically infected with HBV worldwide 
(Seeff and Hoofnagle, 2006), this presents a pressing global health problem that needs greater 
attention. 
 
HBV is a small, partially double-stranded DNA virus belonging to the family of the 
Hepadnaviruses and has a tropism for hepatocytes. The 3.2 kb HBV genome contains four 
partially overlapping open reading frames (ORFs), preS/S, preC/C, P and X. (Figure 1.1A) 
The preS/S ORF encodes the preS1 (Large), preS2 (Middle) and S (small) viral surface 
proteins. The preC/C ORF encodes the core antigen (HBcAg) and the soluble antigen e  
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(HBeAg) while the P ORF encodes the viral polymerase. The smallest ORF is the X ORF 
that is regulated by HBV enhancer 1 and the X promoter and encodes the regulatory X 
protein (HBx). Of the four viral proteins, HBx has been strongly implicated in the 
carcinogenesis process of HBV-associated HCC. HBx is selectively over-expressed (Parkin 
et al., 2005; Poussin et al., 1999) and is the most frequently integrated viral factor in tumours 
of HCC patients (Paterlini et al 1995), highlighting its importance in establishing and 
maintaining viral infection.  
 
1.2 Hepatitis B virus X protein  
1.2.1 Structure of HBx 
The X ORF is regulated by HBV enhancer 1 and the X promoter and encodes the 
small 17 kDa regulatory X protein (HBx). Characterization of the viral X protein has been 
largely hampered by the absence of a three-dimensional structure due to its insoluble nature 
and its weak sequence homology to known motifs and domains. Nevertheless, sequence 
analysis and deletion studies of HBx have provided some insights to its functional domains. 
Several conserved regions comprising amino acid (aa) residues 1-20, 58-84 and 120-140 
were identified by analyzing the X protein sequences of mammalian hepadnavirus. Deletion 
studies of the viral X protein identified a negative regulatory domain at the amino-terminus 
(aa 1-20) (Misra et al., 2004; Murakami et al., 1994) where its cysteine residues have been 
implicated in folding (Rui et al., 2005) or dimerization of the protein (Urban et al., 1997) 
(Figure 1.1B). A trans-activation domain was identified at the carboxy-terminus (aa 48-150) 
that contained essential trans-activation elements of HBx (Kim et al., 1993; Kumar et al., 
1996b; Renner et al., 1995; Takada and Koike, 1990a; Yoo et al., 2004). Also found within 
the trans-activation domain were two regions that exhibited significant homology to the  
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Kunitz domain Kunitz domain




















Figure 1.1. HBV genome and HBx protein. A. Structure of the HBV genome. The partially 
double-stranded 3.2kb viral DNA is depicted by two circular black lines. The black circle 
represents the viral polymerase attached to the 5’ of the minus strand. The 4 arrows represent 
the 4 open reading frames (ORFs) and the rectangles represent the viral enhancers I and II. B. 
The HBx protein. The 154-amino acid HBx protein is depicted by the rectangle and the 
relevant amino acid positions are indicated by the numbers directly below. The regions 
containing the reported functional domains are demarcated by double-arrows. The nuclear 
export signal is abbreviated by NES. Adapted from Cheryl Chan and Caroline G. L. Lee. 
2010, Insights into host transcription modulation by the hepatitis B virus X protein, Trends in 
Cancer Research, Vol. 6, 55-68. 
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Kunitz domain that is characteristic of Kunitz-type serine protease inhibitors, although no 
studies have since confirmed this proposed function of HBx (Takada and Koike, 1990b). 
Additionally, a leucine-rich nuclear export signal motif was mapped to residues 89-100 that 
has been reported to influence the subcellular distribution of HBx in a nuclear export receptor 
Crm1-dependent manner (Forgues et al., 2001). Adjacent to the nuclear export signal is a p53 
binding region (aa 102-136) that was identified by deletion studies to be essential for the 
interaction of HBx with the tumour suppressor p53 protein (Lin et al., 1997b). Spectroscopic 
assays showed that HBx appears to be an unstructured protein and proposed that HBx adopts 
a structured conformation following interaction with host proteins. The structural flexibility 
of HBx is thought to facilitate its interaction with a myriad of host proteins that accounts for 
its multifunctional nature (Rui et al., 2005).  
 
1.2.2 Function of HBx 
HBx is a multifunctional viral regulator. It is conserved in mammalian hepadnaviruses 
and plays a key role in viral replication. This is exemplified by the woodchuck hepatitis virus 
(WHV) genome that is deficient in the X gene (WHx) where viral replication in the animal 
host was found to be either absent (Chen et al., 1993), or compromised, akin to that of 
attenuated viruses (Zhang et al., 2001). Conversely, introduction of HBx in trans restored 
production of viral components in a cell culture model (Nakatake et al., 1993) and restored 
HBx-deficient HBV replication to wild-type levels in an acute hepatitis in vivo mouse model 
(Keasler et al., 2007, 2009). These studies strongly support the important role of the viral X 
protein in HBV replication.  
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HBx is strongly implicated in neoplastic transformation. The multifunctional viral 
protein has been shown to induce neoplastic transformation in various cell culture systems 
(Seifer et al., 1991; Shirakata et al., 1989) and induces HCC in HBx transgenic mice studies 
either alone (Kim et al., 1991; Koike et al., 1994) or in combination with oncogenes such as 
c-Myc (Terradillos et al., 1997), H-Ras (Kim et al., 2001b) or upon exposure to the 
hepatocarcinogen diethylnitrosamine (Madden et al., 2001; Slagle et al., 1996; Zhu et al., 
2004). Moreover, treatment with short-interfering RNAs (siRNAs) that artificially reduced 
HBx expression levels reduced tumour development in nude mice (Chan and Ng, 2006). 
Whether HBx functions as a tumour initiator or a tumour promoter, the pivotal role of HBx in 
cellular transformation and malignancy is evident.  
 
HBx was found largely localized to the cytoplasm in hepatocytes of human liver 
biopsies, while a fraction of hepatocytes contained nuclear HBx (Hoare et al., 2001).Several 
in vitro studies have also detected HBx in association with the mitochondria (Clippinger and 
Bouchard, 2008; Takada et al., 1999). Li et al. identified 7 amino acid residues in the 
carboxy-terminus of HBx (aa 111-117) in which cysteine115 is the most crucial residue for 
mitochondrial targeting (Li et al., 2008). Separately, HBx has also been reported to localize to 
the mitochondria through its interaction with human voltage-dependent anion channel 
HVDAC3, altering mitochondrial transmembrane potential (Rahmani et al., 2000).  
 
Generally, HBx deregulates host processes through direct interaction with host 
proteins in two ways (Doria et al., 1995). On the one hand, cytoplasmic HBx trans-activates 
cellular signalling pathways including MAP kinase signalling (Lin et al., 1997c; Tarn et al., 
2001), Jak1/STAT protein kinase C signalling, transforming growth factor beta (TGF-β) 
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signalling (Lee et al., 2001) and Wnt/β-catenin signalling (Cha et al., 2004). On the other 
hand, nuclear HBx functions as a transcription co-factor that interferes with the regulation of 
host genes. Unlike other DNA viral proteins such as the Epstein-Barr Virus Nuclear Antigen 
1 (EBNA1) that deregulates cellular gene transcription by binding directly to regulatory 
elements of DNA, HBx does not bind DNA directly (Avantaggiati et al., 1993; Siddiqui et 
al., 1989). Instead, HBx is indirectly recruited to DNA through interaction with various 
sequence-specific transcription factors.  
 
Importantly, HBx has been found to interact with various factors that regulate cellular 
transcription. HBx reportedly interacts with components of the basal transcription machinery 
such as RPB5, a common subunit of RNA polymerases (Cheong et al., 1995), TFIIB (Lin et 
al., 1997a), TATA-binding protein TBP (Qadri et al., 1995) as well as ERCC3 and ERCC2 
DNA helicase subunits of TFIIH (Qadri et al., 1996) to stimulate transcription (Maguire et 
al., 1991; Seto et al., 1990; Unger and Shaul, 1990) (Table 1.1). In addition, HBx also 
associates with transcription factors and modulates their DNA-binding characteristics and/or 
transcription activity. Notably, HBx has been reported to associate with and modulate key 
transcription factors that are deregulated in various human cancers including E2F1 (Choi et 
al., 2001; Sung et al., 2009), p53 (Feitelson et al., 1993; Truant et al., 1995a; Wang et al., 
1994a), YY1 (Sung et al., 2009), CREB-binding protein/p300 (Cougot et al., 2007) and the 
bZip family of transcription factors. A list of reported HBx-interacting transcription factors 
and the consequences on transcription regulation are summarized in Table 1.2. Several other 
transcription factors were also identified to mediate HBx-induced gene deregulation but have 
not been shown to directly associate with HBx (Table 1.3). With the exception of the Sp1 
transcription factor that has been shown not to interact with HBx (Lee et al., 1998b), the 
association of HBx with the other transcription factors AP-1, AP-2, NF-κB and Oct-1 





Table 1.1 Summary of components of the basal transcription machinery that interact 




HBx interaction  
Interaction assay References 
in vitro cellular 




Affinity chromatography using Mal-ERCC2 or 
GST-ERCC3 and 
35
S methionine-labeled in vitro 
translated HBx and vice versa 
(Qadri et al., 1996) 
RPB5 Y Y 
Far-Western blotting using GST-HBx or GST-
RBP5; co-IP of transiently transfected HBx and 
RBP5; sedimentation and IP of endogenous RPB5 
and detection of over-expressed HBx 
(Cheong et al., 1995) 
TBP Y N 
GST affinity chromatography using GST-HBx and 
35
S methionine-labeled in vitro translated TBP; co-
IP of HA-tagged TBP and GST-HBx 
(Qadri et al., 1995) 
TFIIB Y Y Far-Western blotting and GST pull-down (Lin et al., 1997a) 
 
^Y and N denote Yes and No respectively; IP denotes immunoprecipitation. Reproduced from Cheryl 
Chan and Caroline G. L. Lee. 2010, Insights into host transcription modulation by the hepatitis B virus X 
protein, Trends in Cancer Research, Vol. 6, 55-68. 
^ 









Interaction assay Effect on gene transcription References 
in vitro cellular 
bZip family      
ATF-2 Y N 
I
125
-labeled recombinant peptides in 
solution to detect direct protein-protein 
interaction with membrane-immobilized 
proteins  
Enhances trans-activation of PEPCK (Kong et al., 2000) 
CREB Y N 
Increases CREB binding to CRE sites; 
enhances trans-activation in CREB-dependent 
assay system; trans-activates IL-8 
(Maguire et al., 1991; 
Mahe et al., 1991; 
Williams and 
Andrisani, 1995) 
ATF-2/CREB Y N 
Increases ATF-2/CREB binding to HBV 
enhancer 
(Maguire et al., 1991) 
ATF3 Y Y 
GST pull-down of GST-HBx and detection 
of 
32
P-labeled bZip proteins; mammalian 
two-hybrid assay 
Increases ATF3 binding to DNA in in vitro 
DNA binding assay, enhances trans-repression 
activity of ATF3 in reporter assay 
(Barnabas et al., 1997; 
Zhou et al., 1994) 
C/EBPβ Y Y 
gadd153/Chop10 Y Y 
ICER IIγ Y Y 
AR N Y 
co-IP of transiently-transfected AR and 
HA-tagged HBx 
Increases AR DNA binding in presence of 
DHT ligand, enhances trans-activation of 
reporter gene 
(Lee et al., 1998a; Su 
and Schneider, 1996) 
C/EBPα Y N 
In vitro DNA binding assay of GST-
C/EBPα and MBP-HBx 
Enhances trans-activation of PPAR-γ, PEPCK 
(Choi et al., 1999; Kim 
et al., 2007; Kong et 
al., 2000) 
E2F1 Y N 
Amylose pull-down assay using MBP-
fused HBx and GST-E2F1 
Trans-activates Rb promoter cooperatively 
with E2F; trans-activates SOAT2 
(Choi et al., 2001; 
Choi et al., 2002; Sung 
et al., 2009) 
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E4F1 Y N 
Yeast two-hybrid assay and GST pull-
down of GST-p120E4F and His-tagged 
HBx 
Reduces trans-activation of reporter gene (Rui et al., 2006) 
HIF-1 Y Y 
GST pull-down assay; co-IP of FLAG-
HBx and GFP-HIF-1α 
Trans-activates MDR1 and carbonic anhydrase 
9  
(Amaro et al., 1999; 
Holotnakova et al., 
2010; Moon et al., 
2004) 
HNF1 Y Y IP of HA-tagged HBx and HNF1 Enhances trans-activation of reporter gene (Weil et al., 1999) 
MAZ Y Y 
GST pull-down assay; co-IP of 
endogenous MAZ and transiently-
transfected tagged HBx/HBx-expressing 
stable cells 
Enhances trans-repression of hTERT (Kim et al., 2001a) 
NF-AT1 Y Y 
GST pull-down assay, co-IP of HA-tagged 
NF-AT1 and Flag-tagged HBx 
Enhances trans-activation of reporter gene (Carretero et al., 2002) 
p53 Y N 
GST pull-down assays with over-expressed 
and endogenous p53  
Inhibits trans-activation of PTEN 
(Feitelson et al., 1993; 
Truant et al., 1995a; 
Wang et al., 1994a) 
SMAD4 Y Y 
GST pull-down assay, co-IP of HBx and 
endogenous SMAD4 in HBx-expressing 
stable cells 
Trans-activates CYP17A1 and trans-represses 
IL17B 
(Park et al., 2006; 
Sung et al., 2009) 
SREBP1 N Y 
Co-IP of HBx and HA-SREBP1c, GST 
pull-down of GST-SREBP1c 
Enhances trans-activation of Fas (Kim et al., 2007) 
YY1 N Y 
Co-IP of transiently introduced HBx and 
endogenous YY1 
Trans-represses AICDA and GRIN2D (Sung et al., 2009) 
RXR Y Y 
GST pull-down assay; mammalian yeast 
two-hybrid assay 
Enhances trans-activation of PEPCK (Kong et al., 2000) 
      
^Y and N denote Yes and No respectively. Reproduced from Cheryl Chan and Caroline G. L. Lee. 2010, Insights into host 
transcription modulation by the hepatitis B virus X protein, Trends in Cancer Research, Vol. 6, 55-68. 




Table 1.3 Summary of transcription factors that have not been shown to interact with HBx, but 
are reported to mediate HBx-induced gene deregulation.  
Transcription 
factor 
HBx effect on gene transcription Remarks References 
AP-1 Enhances trans-activation of c-jun NA (Seto et al., 1990; Zhou et al., 1994) 
AP-2 Enhances trans-activation of TGF-α  NA 
(Kim and Rho, 2002; Seto et al., 
1990) 
NF-κB 
Enhances trans-activation of HIV 
LTR, IL-8, IL-6, iNOS, cyclin D1 
HBx activates NF-κB by acting on 
its cytoplasmic inhibitors, interacts 
with IκBα 
(Amaro et al., 1999; Gomez-
Gonzalo et al., 2001; Kim et al., 
2001a; Lee et al., 1998a; Majano et 
al., 2001; Park et al., 2006; Su and 
Schneider, 1996; Twu et al., 1989; 
Weil et al., 1999) 
Oct-1 
Trans-activates/trans-represses human 
U6 depending on pre-initiation 
complex assembly 
NA (Antunovic et al., 1993) 
Sp1 
Enhances trans-activation of IGF-II, 
reduces trans-activation of XPB, 
enhances trans-repression of XPD 
Reported not to interact with HBx 
using protein affinity 
chromatography, but HBx augments 
DNA-binding activity of 
phosphorylated Sp1  
(Jaitovich-Groisman et al., 2001; 
Lee et al., 1998b) 
 
Reproduced from Cheryl Chan and Caroline G. L. Lee. 2010, Insights into host transcription modulation by the 
hepatitis B virus X protein, Trends in Cancer Research, Vol. 6, 55-68. 
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remains to be investigated. Nevertheless, the numerous reports of transcription factors that 
interact with and are deregulated by HBx highlight the important role of the viral X protein as 
a transcription co-factor in modulating cellular transcription, resulting in aberrant gene 
expression that may contribute to hepatocarcinogenesis. 
 
1.3 HBx and p53 
To understand the transcription co-factor role of HBx in hepatocarcinogenesis, this 
thesis is specifically focused on characterizing the modulation of the transcription factor p53 
by HBx and its consequent effects on p53-regulated gene expression. P53 was chosen for the 
following reasons: firstly, the tumour suppressor protein is widely considered as a master 
regulator of critical cellular processes such as cell cycle arrest, DNA repair, apoptosis and 
senescence. Hence, deregulation of p53-mediated transcription by the viral X protein is of 
great biological significance as this would conceivably upset the maintenance of cellular 
genomic integrity and homeostasis. Although more than 60% of cancers have been reported 
to possess mutated or inactivated p53, p53 mutations in the early stages of HCC are 
infrequent (Feitelson et al., 1993), thus highlighting the relevance of our study. Secondly, 
despite limited literature reports in this field, modulation of p53 by HBx is the most studied 
among the known HBx-interacting transcription factors. Thirdly, the availability of a 
relatively large body of knowledge on general p53 transcription regulation would serve to 
facilitate our study on the deregulation of p53 transcription by the viral X protein. On these 
biologically pertinent and pragmatic bases, the tumour suppressor p53 protein was selected 
for studying the role of the HBx transcription co-factor in contributing to 
hepatocarcinogenesis. To delineate the deregulation of p53 by HBx, it is first imperative to 
expound on the function and regulation of p53. 
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1.3.1 Transcription factor p53 
p53 functions predominantly as a transcription factor that enables the cell to mount an 
appropriate adaptive response to various stress stimuli generally by either arresting the cell 
and repairing the damage, or eliminating the defective cell if the damage is irreparable. In 
unstressed cells, p53 is maintained at low levels by its negative regulator mouse double 
minute 2 (MDM2; HDM2 in humans), an E3 ubiquitin ligase that tags the protein for 
proteasomal degradation. Upon genotoxic stress such as DNA damage, oncogene activation 
and hypoxia, p53 is rapidly stabilized following MDM2 degradation and translocates to the 
nucleus. P53 is also phosphorylated and stabilized by protein kinases such as ataxia 
telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR) and CHK2 that 
are activated in response to genotoxic stress (Figure 1.2). Depending on the stress signal and 
the stress reponse pathways that are activated, the p53 protein is further modified by a host of 
protein modifiers such as CREB-binding protein CBP/p300 and histone deacetylases 
(HDACs) that influence p53 binding site selectivity. Together with other sequence-specific 
DNA-binding transcription factors as well as transcription co-regulators, p53 transactivates or 
transrepresses discrete functional group(s) of target genes to direct an appropriate cellular 
response (Figure 1.2). Examples of p53 target genes that are involved in cell cycle arrest and 
DNA repair include p21 (cdkn1a) and Gadd45A; p53 target genes that are involved in 
apoptosis regulation include Bax, Fas, Puma, p53AIP1 and Noxa.  
 



















Figure 1.2. Illustration of p53-mediated response to cell stress. Various cell stress activate 
different signal mediators that mark p53 post-translationally. Post-translationally-modified 
p53 selectively binds its response element and recruits various transcription co-factors. 
Together, they effect transcription of genes that determine cell fate. Reprinted by permission 
from Macmillan Publishers Ltd. Nat. Rev. Mol. Cell Biol. (Riley et al., 2008) © 2008.
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Figure 1.3 illustrates the various structural domains of the p53 protein. This consists 
of two tandem amino-terminal transactivation domains TAD1 (aa 20-40) and TAD2 (aa 40-
60) at the amino-terminus for transcription activation or repression of p53-responsive genes, 
an overlapping proline-rich domain for interaction with other proteins (aa 40-92), a core 
DNA-binding domain (aa 100-300), a linker region (aa 301-306), a tetramerization domain 
for oligomerization (aa 307-355) and a carboxy-terminal regulatory domain (aa 356-393). A 
nuclear export signal (NES) as well as a nuclear localization signal (NLS) have been found in 
the tetramerization domain and carboxy-terminal domain respectively. 
 
p53 binds as a dimer of dimers (or a tetramer) to DNA in a sequence-specific manner. 
The p53 consensus motif is typically composed of two cognate half-sites that can be 
separated by a spacer sequence of 0-13 base pairs. Each half-site consists of a considerably 
degenerate decamer sequence 5’-RRRCWWGYYY-3’ where R denotes a purine (adenine or 
guanine, A/G), Y denotes a pyrimidine (cytosine or thymine, C/T) and W denotes A/T. Based 
on X-ray crystallography studies, the core RCWWGY motif of the p53 response element was 
found to be in close contact with the amino acid residues of p53 DNA-binding domain and is 
thus regarded as the most important bases for p53-DNA binding (Tang et al., 2006a). 
Particularly important are the C and G nucleotides at positions 4 and 7 respectively of each 
half-site that are highly conserved. Since the p53 consensus sequence was defined, we now 
have a growing list of p53 target genes that contain one or more consensus sites in their 
promoter/intron/exon region. 





















Figure 1.3 Structure of p53. The 393-amino acid p53 protein is depicted by the rectangle and the relevant amino acid positions are indicated by 
the numbers directly below. The regions containing the reported functional domains are indicated. The nuclear export signal is abbreviated by 
NES, nuclear localization signal is abbreviated by NLS. 
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1.3.2 P53 target gene selection 
Binding of p53 to its response elements is spatially and temporally regulated. Also 
referred to as ‘promoter selectivity’, this trait is particularly evident in the response of p53 to 
various stress signals. Depending on the nature and extent of cellular stress, p53 induces 
distinct groups of p53-responsive genes by selectively associating with their promoters to 
elicit the desired response eg. cell cycle arrest or apoptosis. However, how p53 selects for 
some response elements and not others remains the subject of intense investigation. In the 
next section, the three major factors that can influence p53 promoter selectivity are described: 
(i) chromatin structure of the p53 response element, (ii) post-translational modification of the 
p53 protein, and (iii) p53 binding partners.  
 
1.3.2.1 Chromatin structure of p53 response elements 
In eukaryotes, DNA is packaged around histone proteins, forming nucleosomes which 
are the basic repeating units of chromatin. Thus, an obvious structural determinant that 
influences p53 promoter selectivity is the structure of the chromatin of the region 
encompassing the p53 response element of the target genes. It has been shown that some p53 
response element-containing regulatory regions exist in a constitutively ‘open’ (nucleosome-
free) conformation and hence accessible for p53 binding, while others exist in a ‘closed’ 
conformation, occluded by nucleosomes that render them inaccessible for p53 binding. 
Chromatin structure can be altered by ATP-dependent chromatin remodelers such as 
SWI/SNF, Polycomb and nucleosome remodelling and histone deacetylase (NuRD) 
complexes that alter nucleosome positioning along DNA, as well as factors that covalently 
modify histones such as histone acetyltransferases/deacetylases and 
methyltransferases/demethylases. These alter DNA accessibility to transcription regulators 
that consequently influences gene transcription. Notably, both chromatin remodelers and 
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histone modifiers have been implicated in oncogenesis and cancer progression (Lai and 
Wade, 2011). Of special mention is the NuRD complex of proteins. In addition to its ATP-
dependent chromatin remodelling activity, the NuRD complex also possesses lysine 
deacetylase activity conferred by histone deacetylases HDAC1 and HDAC2 that has been 
shown to deacetylate lysine residues of the p53 protein, and inhibit p53-dependent 
transcriptional activation and its function in growth arrest and apoptosis (Kew, 2011). 
 
1.3.2.2 p53 post-translational modifications 
The p53 protein is extensively post-translationally modified (Figure 1.4). At least 21 
different serine (Ser) and threonine (Thr) residues of p53 have been reported to be modified 
by phosphorylation. Majority of these residues are located at the amino-terminal trans-
activation domain and the carboxy terminal regulatory domain and phosphorylation at these 
sites are thought to stabilize the p53 protein in response to stress. Moreover, p53 can be 
ubiquitinated at several lysine (Lys) residues residing mostly at the carboxy terminal 
regulatory domain. Mono-ubiquination at these sites has been shown to facilitate nuclear 
export of the p53 protein (Carter et al., 2007) while poly-ubiquitination is known to target 
p53 for proteasomal degradation (Li et al., 2003). Additionally, Lys residues at the 
tetramerization domain and carboxy-terminus regulatory domain of p53 can also be 
acetylated and have been shown to influence p53 sequence-specific DNA binding selectivity 
(Gu and Roeder, 1997; Liu et al., 1999; Luo et al., 2004; Sakaguchi et al., 1998a). Lastly, 
p53 can also be altered by methylation, sumoylation (Chen and Chen, 2003; Gostissa et al., 
1999; Rodriguez et al., 1999; Schmidt and Muller, 2002) and neddylation (Abida et al., 2007; 
Xirodimas et al., 2004), highlighting the myriad of post-translational modifications that 
regulate the p53 protein. 











Figure 1.4. p53 post-translational modifications. Phosphorylation (P), acetylation (Ac), ubiquitination (Ub), sumoylation (SU), neddylation 
(N) and methylation (M) of p53 amino acid (aa) residues throughout the protein. Transactivation domain 1/2 (TAD1/TAD2), proline-rich 
domain (PRD), DNA-binding domain (DBD), tetramerization domain (4D) and carboxy-terminal domain (CTD) of p53. Reprinted by 
permission from Macmillan Publishers Ltd. Cell Death Differ. (Olsson et al., 2007) © 2007. 
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Importantly, regulation of p53 by post-translational modifications has been shown to 
influence its target gene selection that directs a particular cellular outcome (Appella and 
Anderson, 2001; Jansson et al., 2008). It has been reported that specific factors/pathways are 
activated in response to specific cell stresses that converge on the p53 in the form of a ‘p53 
post-translational code’ to selectively activate (or repress) transcription of the appropriate 
functional group of genes to elicit the desired cellular response. For instance, ATM-
dependent phosphorylation of p53 at Ser15 in response to γ-irradiation selectively 
transactivated genes that are involved in growth arrest and apoptosis (Banin et al., 1998; 
Siliciano et al., 1997).  
 
Another example of p53 target gene selection by post-translational modifications is 
the phosphorylation of p53 Ser46 by various kinases such as protein kinase C delta 
(PKCdelta) (Chuikov et al., 2004), dual-specificity tyrosine phosphorylation-regulated kinase 
(DYRK) (Oda et al., 2000) and homeodomain-interacting protein kinase 2 (HIPK2) (Gu and 
Roeder, 1997) that are activated upon DNA damage. Phosphorylated Ser46 has been reported 
to specifically stimulate transcription of the pro-apoptotic gene p53AIP1 (Oda et al., 2000). 
The mechanism by which p53 phosphorylation modulates transcription of its target genes 
however, remains to be clarified. Acetylation of p53, on the other hand, has been shown to 
alter its sequence-specific DNA-binding property. It is thought that such modifications of p53 
induce conformational changes in the protein that alter its affinity for response elements with 
particular DNA structural characteristics. For example, Knights et al. demonstrated that 
different p53 acetylation patterns show varying affinities for different types of p53 response 
elements that are associated with specific cellular outcomes (Knights et al., 2006). The 
authors reported that acetylated-p53 Lys373 exhibited a preference for low-affinity binding 
sites that were found in several pro-apoptotic genes, thereby promoting cell death; 
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contrastingly, acetylated-p53 Lys320 exhibited a preference for high-affinity binding sites 
such as that of p21, thus promoting cell survival. These studies highlight the biological 
relevance of the various post-translational modifications in regulating p53-mediated 
transcription.  
 
Clearly, the myriad of p53 post-translational modifications presents an intricate 
mechanism for fine-tuning p53 transcription regulation. Although the aforementioned 
examples illustrate simply the role of post-translational modifications in regulating p53 target 
gene selection, the p53 post-translational code is far more complicated. Firstly, each 
modifying factor, for example ATR, can phosphorylate multiple p53 Ser residues including 
Ser15 and 37. Secondly, various post-translational modifications can ‘compete’ for the same 
p53 residue. For instance, p53 Lys320 can be acetylated by p300/CBP-associated factor 
PCAF (Sakaguchi et al., 1998a) or ubiquitinated by E3 ligase E4F1 (Le Cam et al., 2006), 
while p53 Lys372 can be acetylated by CBP/p300 (Gu and Roeder, 1997), ubiquitinated by 
MDM2 (Nakamura et al., 2000) or methylated by SET9 (Chuikov et al., 2004). Thirdly, 
crosstalk also exists between the various post-translational modifications. Upon severe DNA 
damage, p53 is phosphorylated at Ser46 and this modification has been shown to induce 
acetylation at p53 Lys382, promoting apoptosis (Hofmann et al., 2002; Puca et al., 2009). 
Lastly, examination of various p53 post-translational modifications in knock-in animal 
models - albeit in limited cell types and on limited p53 target genes - have surprisingly 
revealed generally modest phenotypic changes, alluding to possible compensatory 
mechanisms in vivo. Nevertheless, a dynamic combination of p53 post-translational 
modifications can be induced in response to various stress stimuli that may influence p53 
promoter selectivity to direct an appropriate cellular response.  
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1.3.2.3 p53 binding partners  
Another factor that has been described to influence p53 promoter selectivity is its 
context-specific interaction with various protein partners such as members of the ASSP 
family, Brn3 family of POU domain transcription factors, Y-box binding protein YB1, NFkB, 
BRCA1 and Pin1. Interestingly, association of p53 with Brn-3b stimulated pro-apoptotic bax 
expression while association of p53 with Brn-3a repressed bax expression but augmented 
transactivation of p21, driving cell fate towards cell cycle arrest (Elmore et al., 1997; Lee et 
al., 2005a; Scheffner et al., 1990). Similarly, ASSP family members ASSP1 and ASSP2 were 
reported to selectively stimulate p53 binding to promoters of pro-apoptotic genes bax and 
Pig3 but not to that of cell cycle arrest genes cdkn1a and mdm2 while interaction of p53 with 
an anti-apoptotic ASSP family member iASSP inhibited transactivation of these pro-
apoptotic genes (Scheffner et al., 1993; Woo et al., 2011). Notably, the interaction of p53 
with selected binding partners can also be affected by post-translational modifications of the 
p53 protein. This is exemplified by the interaction between p53 and Pin1. Following 
genotoxic stress, the prolyl isomerase Pin1 specifically recognizes p53 phosphorylated at 
Ser46, displacing iASSP from p53 that drives cells towards apoptosis (Ryoo et al., 2004; 
Zheng et al., 2002). Hence, a complex interplay of structural and regulatory factors is likely 
to be involved in p53 target gene selectivity. 
 
1.3.3 p53-mediated transcriptional repression 
In addition to transcriptionally activating its target genes by binding and recruiting 
general transcription factors as well as histone modifiers to their promoter and/or enhancer 
regions, p53 can also transcriptionally repress its target genes. P53-mediated transcriptional 
repression however is less well defined.  
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Several mechanisms have been proposed to account for its direct transrepressive 
function. Firstly, binding of p53 to its response element can occlude overlapping or adjacent 
binding sites of other strong transcriptional activators, thus preventing their recruitment and 
abrogating their stimulatory effect of the target gene. This is evident from the mutually 
exclusive binding of p53 and hepatic nuclear factor HNF-3 at the repressor domain of alpha-
fetoprotein (AFP) gene. HNF-3 recruitment stimulated AFP transcription while p53 
sequence-specific binding conversely repressed AFP transcription (Liu et al., 2000). 
Secondly, p53 can also repress transcription by recruiting and cooperating with transcription 
co-repressors such as the aforementioned histone deacetylases (Harrod et al., 2003; Martinez-
Balbas et al., 2000). Another example is the interaction of p53 with YY1 that disrupts the 
association of p53 with the co-activator p300, abrogating transcription of the target gene 
(Tang et al., 2006b). In addition, some studies suggest that the DNA sequence of the p53 
response element itself can determine whether p53 activates or represses gene transcription. 
Interestingly, a study that analyzed the spacer lengths of validated p53 response elements 
showed that sites associated with p53-mediated transcription repression (or repressor sites) 
contained motifs with longer spacers as compared to sites associated with transcription 
activation (or activator sites) (O'Connor et al., 1995; Sykes et al., 2006). Separately, another 
study reported that p53 transcriptional response was determined by the orientation of its 
quarter-sites (Brandner, 2010). However, these DNA sequence-centric theories are unable to 
predict transcription outcomes of p53-regulated genes that have a more complex regulatory 
landscape. For instance, some p53-responsive genes such as p21 (Mertens et al., 2002) and 
PERP (McPherson et al., 2002; Sala et al., 1996) harbour multiple functional p53 response 
elements in their regulatory region. Furthermore, not all p53-DNA binding events affect gene 
transcription. These studies thus underscore the complexity of p53-mediated transcription 
regulation that is currently still under investigation.  
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1.3.4 HBx modulation of p53 
HBx interacts with p53 and alters its sequence-specific DNA binding that is associated 
with deregulated gene expression. Various studies to date however, report differing effects of 
HBx on p53-DNA binding. HBx was demonstrated to inhibit p53 sequence-specific DNA 
binding in in vitro DNA binding assays and reporter assays (Knights et al., 2006; Ogden et 
al., 2000b; Wang et al., 1994a). In contrast, a study by Truant et al. showed that HBx 
enhanced p53 oligomerization on DNA oligonucleotide (Truant et al., 1995a). Importantly 
however, the modulation of p53 sequence-specific DNA binding by HBx resulted in aberrant 
expression genes that have been implicated in heptocarcinogenesis. For example, HBx was 
reported to disrupt p53-mediated transcription of a tumour suppressor PTEN in cellular 
promoter assays, possibly by decreasing p53 binding to its response element at the PTEN 
promoter (Chung et al., 2003). Although these few initial studies provided invaluable insights 
to the co-factor role of HBx in modulating p53 in hepatocarcinogenesis, little progress has 
been made since to meticulously characterize this modulation as well as to elucidate the 
mechanism of deregulation of the viral protein. 
 
1.4 p53AIP1 and the role of HBx in apoptosis 
1.4.1 p53AIP1 
 Our initial study identified the pro-apoptotic bona fide p53 target gene p53-regulated 
apoptosis-inducing protein p53AIP1 to be deregulated by HBx in a p53-dependent manner. In 
this thesis, p53AIP1 is used as a model to study the modulation of p53 by HBx and the 
mechanism(s) underlying this deregulation. 
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P53AIP1 was first discovered through direct cloning of p53 binding sequences from 
human genomic DNA by Oda et al. Its expression was demonstrated to be induced by p53 
and a functional p53 response element that was identified in the intron1 region of the gene 
was implicated in its p53-mediated transactivation (Feitelson et al., 1993). Significantly, the 
authors identified a unique DNA damage-inducible, site-specific phosphorylation of p53 at 
Ser46 that selectively stimulated p53AIP1 transcription. They further demonstrated that 
Ser46-phosphorylated p53 selectively bound to the intron 1 p53 response element of p53AIP1 
but not to that of p21, implicating the p53 site-specific post-translational modification in p53 
promoter selectivity and apoptosis induction. Since, various kinases such as protein kinase C 
delta (PKCdelta) (Chuikov et al., 2004), dual-specificity tyrosine phosphorylation-regulated 
kinase (DYRK) (Oda et al., 2000) and homeodomain-interacting protein kinase 2 (HIPK2) 
(Gu and Roeder, 1997) have been shown to phosphorylate p53 at Ser46 in response to DNA 
damage. The consequent increase in p53AIP1 expression promoted apoptosis through the 
mitochondrial apoptotic pathway by disrupting the mitochondria membrane potential, 
resulting in cytochrome c release (Feitelson et al., 1993; Sakaguchi et al., 1998b).  
 
1.4.2 The role of HBx-in p53-mediated apoptosis 
 P53 can initiate apoptosis, or programmed cell death, in response to a variety of 
stimuli including as viral infection and cell stress to eliminate damaged cells. Two apoptotic 
pathways have been described: the extrinsic pathway that responds to external stress signals 
through engaging cell surface ‘death receptors’, and the intrinsic pathway that alters responds 
to signals within the cell that alters mitochondrial membrane permeability through an 
interplay of pro- and anti-apoptotic regulators. The extrinsic and intrinsic pathways converge 
by activating caspases – a family of cysteine proteases that are key to the cell death 
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machinery in executing apoptosis and effecting cellular destruction. Evasion of apoptosis has 
long been considered one of the hallmarks of cancer. Recent reports however suggest that 
apoptosis can either promote or suppress tumourigenesis depending on the context and cell 
type examined.   
 
Although there have been contradicting reports of the viral X protein in p53-mediated 
apoptosis, an increasing body of work points towards the pro-apoptotic role for HBx. Several 
initial studies described that HBx abrogates p53-mediated apoptosis (Knights et al., 2006; Liu 
et al., 1999; Sakaguchi et al., 1998a). A subsequent study using stably-expressing HBx in 
various cell lines demonstrated that the effect of HBx on apoptosis induction might be cell 
type-dependent (Luo et al., 2004). This study reported that an immortalized murine 
hepatocyte cell line AML12 stably expressing HBx showed a reduction in apoptosis, while a 
HBx stable human hepatoma cell line HepG2 exhibited enhanced apoptosis. Over the years, 
more and more reports have consistently shown that the viral protein is involved in apoptosis 
induction. The earliest reports advocated a pro-apoptotic role of the viral X protein both in 
cells stably-expressing HBx (Feitelson et al., 1993; Wang et al., 1994b) as well as in 
transiently-expressing HBx cells (Truant et al., 1995b). Wang et al. demonstrated that HBx 
sensitised hepatocytes to p53-mediated apoptosis through activating the p38 mitogen-
activated protein kinase (MAPK) pathway that stabilized as well as enhanced transcription of 
p53, resulting in stimulated transcription of pro-apoptotic genes Bax, Fas and Noxa (Elmore 
et al., 1997; Lin et al., 1997b). We and others have independently demonstrated that HBx 
sensitised cells to programmed cell death after DNA damaging treatment (Chao et al., 2006; 
Ogden et al., 2000a; Yun et al., 2000). Recently, HBx was shown to induce apoptosis in 
tumour cell lines but not in non-tumorous cell lines (Lee et al., 1995). From these studies, it is 
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becoming apparent that HBx induces p53-mediated apoptosis but how this facilitates 
hepatocarcinogenesis is still being intensely researched.  
 
1.5. Technological advancement 
1.5.1 Chromatin immunoprecipitation and expression profiling 
Traditional approaches used to characterize the modulation of p53-DNA binding by 
HBx as described above were analyzed mainly in an artificial context using oligonucleotide 
templates and purified proteins in in vitro DNA binding assays as well as mutagenesis studies 
and reporter assays. Significantly, the advent of chromatin immunopreciptation (ChIP) assay 
enabled protein-DNA interactions to be examined in a physiological context. This assay is 
now used widely to capture transcription factor-DNA interactions in its native environment, 
that is, in the context of the chromatin structure and cellular milieu. In ChIP, DNA-binding 
proteins are cross-linked to DNA and protein-DNA complexes are immunoprecipiated using 
an antibody specific for the protein of interest. Cross-links are reversed and the regions bound 
by the transcription factor (also known as ChIP-enriched DNA) can be recovered and 
quantified by quantitative real-time PCR. Moreover, recent advancement of technological 
platforms to detect ChIP-enriched DNA on a genome-wide scale such as using high density 
genome-wide tiling arrays (ChIP-on-chip) as well as massive parallel sequencing (ChIP-Seq) 
has afforded unprecedented capacity in mapping the binding sites of the transcription factor 
of interest. As the technology developed and became more cost-effective over the last few 
years, global maps of transcription factor binding sites have been elucidated. In addition, 
integration of genome-wide transcription factor-DNA interaction profiles with global gene 
expression profiles obtained using gene expression microarrays have facilitated the 
identification of direct gene targets of the transcription factor of interest (collectively known 
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as regulatory modules) (Abida et al., 2007; Feng et al., 2005; Lin et al., 1997b; Sung et al., 
2009; Terui et al., 2003). Furthermore, bioinformatics analysis of the binding profile of a 
particular transcription factor can reveal other adjacent co-enriched transcription factors that 
co-operate with the transcription factor of interest (collectively termed co-regulatory 
modules). This strategy proved successful in identifying transcription factors that co-operate 
with SMAD in a context specific manner (SMAD co-regulatory modules) (Qin et al., 2009) 
as well as co-regulatory modules of OCT4 and SRY (Nakatake et al., 1993).  
 
In addition to analysing the direct binding of a transcription factor of interest to DNA, 
ChIP has enabled the detection of proteins that bind DNA indirectly. As samples are cross-
linked prior to ChIP, we can now capture huge protein complexes in association with DNA. 
This has been particularly useful in examining the transcription co-factor function of HBx. 
Previous work in our lab had demonstrated that ChIP using high-affinity HBx-specific 
antibodies successfully elucidated patterns of HBx indirect binding to DNA as well as HBx 
direct gene targets (Sung et al., 2009). As HBx indirectly binds DNA through association 
with sequence-specific DNA-binding transcription factors, our lab had successfully used 
HBx-ChIP coupled with bioinformatics analysis to identify these HBx-interacting 
transcription factors such as E2F1, YY1 and SMAD4 that mediate the indirect binding of 
HBx to DNA. Furthermore, integration of global HBx-ChIP with expression profiling 
enabled the identification of target genes directly deregulated by HBx. Similarly, the binding 
profiles of transcription co-regulators such as histone deacetylases and acetyltransferases that 
bind DNA indirectly can also be examined using ChIP with the antibody specific for the 
factor of interest. 
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Thus, the advancement of technological platforms for genome-wide mapping of 
transcription factor binding sites together with the current widespread application of 
microarray profiling of global gene expression have brought with it an enormous capacity to 
uncover the complex regulatory circuits that govern cellular gene expression, and hence its 
deregulation.  
 
1.5.2 Experimental tools in our lab 
Research in the field of HBx has been largely hampered by the lack of high-affinity 
antibodies specific for the viral protein. Importantly, our lab has generated high affinity HBx-
specific antibodies that have been shown to be amenable for use in various applications 
including immunoblotting, immunocytochemistry and immunoprecipitation (Chao et al., 
2006). Moreover, a recombinant HBx-expressing adenoviral system was also developed in 
our lab to efficiently introduce the viral X protein into HepG2 liver cells (Figure 1.5A) and 
that expresses HBx at physiologically relevant levels (Chao et al., 2006) (Figures 1.5B and 
C).  
 
















































Figure 1.5. Experimental tools. A. Images of UV-treated HepG2 cells transduced with 
either control or HBx-expressing recombinant adenovirus. This research was originally 
published in The Journal of Biological Chemistry. Lee et al. The hepatitis B virus X protein 
sensitizes HepG2 cells to UV light-induced DNA damage. J Biol. Chem. 2005, 280(39): 
33525-35. © the American Society for Biochemistry and Molecular Biology. B. Immunoblot 
of HepG2 cell lysates probed with antibodies specific for HBx and GAPDH. C and H denote 
control and HBx cell lysates respectively; N and T denote non-tumorous and HCC tumour 
lysates respectively. C. Range of HBx protein expression levels in HCC tumourous liver 
samples and in HBx-expressing HepG2 cells. 
A 
B C 
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1.6 Objectives of this thesis 
In this thesis, I sought to accomplish three main objectives to elucidate the role of 
HBx in hepatocarcinogenesis that are outlined below: 
1.  To identify patterns of modulated p53-DNA binding that are linked to p53 target 
gene deregulation by HBx. To this end, a cell culture HBx model was employed 
for p53 ChIP-on-chip and expression profiling (Figure 1.6). A known p53 target 
gene p53AIP1 identified from this study that was deregulated by HBx with 
associated altered p53 binding at its regulatory region was selected for further 
characterization. 
2. To characterize the p53-mediated deregulation of p53AIP1 by HBx. Mutagenesis 
and promoter studies were used to systematically investigate the effect of HBx-
induced altered p53-DNA binding on target gene expression. Furthermore, the 
functional and clinical importance of p53AIP1 deregulation were also addressed. 
3. To elucidate the mechanism by which HBx modulates p53 with respect to 
p53AIP1 deregulation. Using a computational approach complemented by 
experimental validation, we define a novel mechanism of HBx in altering p53 
sequence-specific DNA binding that involves an interplay of differential 
transcription co-regulator recruitment and p53 post-translational modification(s). 
 




Genome-wide p53 chromatin 
Immunoprecipitation









II. Identify deregulated genes




Cy3-labelled cDNA from 
control-infected cells




Figure 1.6. Illustration of our strategy to identify HBx-modulated p53-DNA binding with associated gene deregulation. Differential p53-
DNA binding was identified by p53 chromatin immunoprecipitation using on control and HBx-expressing cells coupled with microarray or 
sequencing. HBx-deregulated genes were identified by expression array profiling. 
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1.7 Significance of this thesis 
 In delineating the oncogenic transcription co-factor function of the hepatitis B virus X 
protein, we present first evidence that HBx alters global p53 sequence-specific DNA binding 
properties that were linked to corresponding deregulated gene expression patterns. We 
observed that HBx enhanced, alleviated as well as induced a novel shift p53-DNA binding at 
the regulatory regions of genes and that these changes associated with alterations in their 
expression.  
 
Using a validated candidate from the global study - a known p53-regulated gene 
p53AIP1 as a model, I further characterized the role of HBx in modulating p53 sequence-
specific binding and transcription regulation. I have demonstrated that HBx deregulates 
p53AIP1 through a novel shift in p53-DNA binding at its regulatory region. Additionally, I 
have shown that p53AIP1 expression is also aberrantly increased in tumours of HCC patients 
with high HBx expression, highlighting the relevance of our finding in hepatocarcinogenesis. 
Moreover, I have demonstrated the functional importance of increased p53AIP1 expression in 
mediating HBx-induced apoptosis in vitro, emphasizing the potential of HBx-induced p53 
transcription deregulation in disrupting cellular homeostasis. 
 
 Significantly, our findings further define a mechanism of action for the viral X protein 
in deregulating p53 transcription. I have shown by using p53AIP1 as a model, that HBx 
perturbs the recruitment of distinct p53-associated transcription co-factors that result in the 
differential recruitment of co-regulators such as lysine deacetylases and acetyltransferases. 
This shift in turn feeds back into p53, altering the ‘post-translational code’ of the p53 protein 
that modulates its sequence-specific DNA-binding selectivity.  The combination of HBx-
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altered transcription co-factor/co-regulator recruitment as well as altered p53 post-
translational modifications culminates in deregulated p53-mediated gene expression. This 
work presents a significant advancement in our understanding of the co-factor function of 
HBx in modulating the tumour suppressor protein p53, since the mechanism of action of the 
viral X protein had been largely unknown.  




To identify patterns of 
modulated p53-DNA binding 
that are linked to p53 target 
gene deregulation by HBx
HBx modulates p53-DNA binding with 
associated gene deregulation 
p53 ChIP-on-chip and 
expression profiling
HBx induces a novel shift in p53-DNA 
binding at p53AIP1
ChIP-qPCR 
Altered p53-DNA binding by HBx 
deregulates p53AIP1
Mutagenesis studies 
Promoter assays            
RNA interference studies       
qRT-PCR
p53AIP1  is increased in HCC patients 
with high HBx status
Immunoblotting               
qRT-PCR
p53AIP1  mediates HBx-induced 
apoptosis
RNA interference studies 
Apoptosis assay       
(annexin V/7AAD staining 
and FACS analysis) 
HBx does not alter p53 Ser46 
phosphorylation
Immunoblotting       
HBx alters transcription factor/co-regulator 
recruitment
Bioinformatics            
ChIP-qPCR                            
Mutagenesis studies 
Promoter assays            
RNA interference studies
HBx generally does not alter transcription 
factor/coregulator protein levels
Immunoblotting
HBx does not alter chromatin state of 
p53AIP1 regulatory region
Acetylated H3/H4        
ChIP-qPCR                                   
DNA methylation profiling
HBx enhances PCAF-mediated p53 
Lys320 acetylation that alters sequence-
specific DNA binding
Immunoblotting               
ChIP-qPCR             
Mutagenesis studies                   
RNA interference studies                  
p53 ChIP-Seq
To characterize the p53-
mediated deregulation of 
p53AIP1  by HBx 
To elucidate the mechanism 
by which HBx modulates p53
Table 1.4. Overview of thesis 
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Actin (I-19) Santa Cruz sc-1616 1:10,000 Goat polyclonal
EGFP Roche 11814460001 1:20,000 Mouse monoclonal
GAPDH Millipore ABS16 1:20,000 Rabbit polyclonal
GATA-1(H-200) Santa Cruz sc-13053 1:5,000 Rabbit polyclonal
HBx 1:10,000 Rabbit polyclonal
HDAC1 (H-51) Santa Cruz sc-7872 1:10,000 Rabbit polyclonal
p53 (DO-1) Santa Cruz sc-126 1:10,000 Mouse monoclonal
PCAF (E-8) Santa Cruz sc-13124 1:5,000 Mouse monoclonal
Acetyl-p53 (Lys 320) Millipore 06-1283 1:5,000 Rabbit polyclonal
Acetyl-p53 (Lys 373) Millipore 06-916 1:5,000 Rabbit polyclonal
Acetyl-p53 (Lys 380) Millipore 04-1146 1:5,000 Rabbit monoclonal
Phospho-p53 (Ser 46) Cell Signaling 2521 1:100 Rabbit polyclonal
Sp1 (1C6) Santa Cruz sc-420 1:1,000 Mouse monoclonal













Goat anti-mouse IgG,      
HRP conjugated
Pierce 1:100,000 Goat polyclonal
Goat anti-rabbit IgG,     
HRP conjugated
Pierce 1:100,000 Goat polyclonal
Rabbit anti-goat IgG,     
HRP conjugated
Pierce 1:100,000 Rabbit polyclonal
 
 


































p53 Cloning and Mutagenesis
K320Q mutant
K320R mutant
Promoter Cloning and Mutagenesis
p53AIP1  wild-type promoter









p53AIP1  promoter p53 RE
p53AIP1  intron 1 p53 RE
RT-qPCR
Table 2.3 List of primers used in thesis.  
Mutations introduced are denoted by lower case. RE denotes response element. F and R 
denote forward and reverse primers respectively. 
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 2.1 Mammalian cell culture and assays 
2.1.1 Mammalian cell culture 
All cell lines used in this thesis were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). Human HCC cell lines HepG2 (p53 wild-type) and Hep3B (p53-
deficient) as well as human embryonic kidney HEK293 cells (ATCC CRL-1573) were 
cultured in Dulbecco’s Modified Eagle Medium (Gibco/Invitrogen, Carlsbad, CA) 
supplemented with 10% FBS. Non-transformed immortalized human liver cells THLE-3 
(ATCC CRL-11233) that have near diploid karyotypes and lack alpha-fetoprotein expression 
were maintained in bronchial epithelial basal medium media (Clonetics, San Diego, CA) 
without addition of Gentamycin/Amphotericin and Epinephrine and supplemented with 10 
ng/ml EGF, 100 ng/ml Phosphoethanolamine and 10% FBS. Flasks and plates used for 
propagation of THLE-3 cells were coated with 0.03 mg/ml rat tail collagen type I. All cells 
were incubated in a humidified atmosphere at 37˚C, 5% CO2.  
 
2.1.2 Recombinant adenovirus transduction of cells 
2.1.2.1 Construction of recombinant adenoviruses  
An invaluable experimental tool used in this thesis is the control and HBx-expressing 
recombinant adenoviral system that facilitated efficient introduction the viral X protein into 
liver cells (Figure 2.1). As described previously (Murakami, 2001), the HBx gene was 
amplified from pEco63 plasmid, cloned into a pAdTrack-CMV shuttle vector and its integrity 
was verified by sequencing. The HBx-containing pAdTrack-CMV-HBx or control pAdTrack-
CMV vectors were linearized using PmeI and subsequently co-transformed with enhanced 
green fluorescence protein (EGFP) gene-containing pAdEasy-1 plasmid into BJ5183 E. coli 
cells. Control and HBx-expressing recombinant adenoviral vectors were obtained by 
homologous recombination of the two vectors pAdEasy-1 and pAdTrack-CMV/pAdTrack-
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CMV-HBx respectively, and successful recombination events were screened using EcoRV 
and PmeI restriction endonuclease analyses. Following enzymatic digestion by PacI, the 
pAdControl and pAdHBx vectors (Figure 2.1A) were transfected into HEK293 cells that 
constitutively express the adenoviral E1 gene product for packaging into control and HBx-
expressing recombinant adenoviruses respectively. 
 
2.1.2.2 Propagation and titration of recombinant adenoviruses 
Recombinant HBx and control adenoviruses were propagated and titrated using 
HEK293 cells. Essentially, cells were transduced with HBx and control viruses and harvested 
after 48 hr. Multiple rounds of freeze-thaw were performed to lyse cells. Supernatants 
containing the released viruses were stored in aliquots in -80˚C. To determine the titre of each 
batch of HBx and control viruses generated, 2.5 x 10
5
 HEK293 cells were seeded in each well 




) performed in 
quadruplicates, 24 hr post-seeding. The titre of the viruses was determined by visually 
counting the number of cells with green fluorescence in each well and expressed as 
expression-forming units/per ml. 
 
2.1.2.3 Determination of multiplicity of infection for transduction 
Cells were transduced with a range of multiplicity of infection (MOI) of recombinant 
HBx and control viruses (MOI of 0, 2, 4, 6, 8 and 10). Dark field and phase contrast images 
were taken 24 hr post-transduction (Figure 2.1B) and cells were harvested and lysed for 
EGFP quantification by western blotting (Figure 2.1C). Appropriate MOIs for HBx and 
control adenovirus transduction for each cell line were determined using the following 
criteria: a) high transduction efficiency (>90%), b) minimal cytotoxicity and c) comparable 
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Figure 2.1. Control and HBx-expressing recombinant adenoviral system. A. Shown are 
schematic diagrams of the pAdControl and pAdHBx constructs used to generate the 
recombinant adenoviruses. This research was originally published in The Journal of 
Biological Chemistry. Lee et al. The hepatitis B virus X protein sensitizes HepG2 cells to UV 
light-induced DNA damage. J Biol. Chem. 2005, 280(39): 33525-35. © the American Society 
for Biochemistry and Molecular Biology. B and C. Control and HBx-transduced THLE-3 
cells using a range of multiplicity of infection (MOI), from 0 to 10. B. Western blots of EGFP 
and actin loading control of the indicated protein lysates. C. Shown are dark field and phase 
contrast images of cells transduced with the indicated MOIs.  
A B 
C 
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EGFP levels between cells transduced with HBx and control adenoviruses. Importantly, 
MOIs were chosen that reflected physiologically relevant HBx-expression levels 
(Figure1.5B). MOI of 6 and 10 for control and HBx-expressing recombinant adenovirus 
respectively were used for all subsequent experiments.  
 
2.1.3 Ultraviolet treatment of HepG2 cells 
As described previously, HepG2 cells were exposed to UVC (254 nm) irradiation for 30 
sec with a germicidal lamp calibrated to deliver 8 J/m
2
 48 hr post-transduction (Chao et al., 
2006). Cells were harvested 24 hr post-UV irradiation. 
 
2.1.4 Transient transfection methods 




 cells were seeded in each well of a 6-well plate. 100 μM of short interfering 
RNAs (siRNAs) and/or 1-5 μg of plasmid DNA were chemically introduced to the cells 24 hr 
post-seeding using siPORT
TM
 Amine Transfection Agent (Ambion, Austin, TX, USA) 
according to the manufacturer’s protocol. Briefly, siPORTTM Amine Transfection Agent was 
diluted in OPTI-MEM I
® (Invitrogen) reduced serum media in a 9 μl:100 μl ratio and 
incubated for 10 min at room temperature. Separately, siRNA and/or plasmid DNA was 
appropriately diluted in 100 μl OPTI-MEM I®. Diluted siPORTTM Amine Transfection Agent 
was subsequently mixed with the diluted siRNA and/or plasmid DNA by gentle pipetting up 
and down, and incubated for 30 min at room temperature. The nucleic acid/ siPORT
TM
 Amine 
transfection complexes were then added onto the adherent cells that were pre-washed with 
PBS and replaced with fresh culture media. 
 
Cells were harvested 24 hr post-transfection 
unless otherwise indicated. SiRNAs specific for TP53 (s605), TP53AIP1 (241781) and 
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GATA-1 (s5595) as well as negative control scramble siRNA (AM4611) were purchased 
from Ambion. siRNAs specific for PCAF (sc-36198), Sp1 (sc-44221) and YY1 (sc-36863) 
were purchased from Santa Cruz Biotechnology, CA, USA. 
 
2.1.4.2 Electroporation of siRNA and plasmid DNA into HepG2 cells 
2 x 10
6
 cells were used for electroporation experiments. Cells were trypsinized, washed 
once with PBS, resuspended in 200 μl OPTI-MEM I®. Appropriate amounts of siRNA and/or 
plasmid DNA was added into the cell suspension, gently mixed by tapping and subsequently 
transferred to a 4 mm BTX Electroporation Cuvette Plus™ (BTX® Harvard Apparatus, Inc., 
Holliston, MA, USA) and placed on ice. Cells were electroporated using a ECM 830 Square 
Wave Electroporator (BTX) using the following settings: Low voltage mode, 180 volts, 100 
msec. Following electroporation, cuvettes were immediately placed back on ice. Cells were 
gently resuspended in fresh culture media and seeded in the respective wells of a 6-well plate. 
Cells were harvested 24 hr post-transfection unless otherwise stated. 
 
2.1.5 Beta-galactosidase reporter assay 
P53AIP1 promoter activity was assayed in p53-deficient Hep3B cells in which the 
effect of exogenously introduced p53 can be consistently tested. 5 μg of beta-galactosidase 
(β-gal) reporter construct (wild-type WT, mutants M1, M2 or M3), 1 μg TP53-expressing or 
control plasmid, and/or 100 μM TP53-specific or control siRNA was chemically introduced 
to Hep3B cells 24 hr post-seeding using siPORT
TM
 Amine Transfection Agent (Ambion) 
according to the manufacturer’s protocol. Cells were harvested 24 hr post-transfection. 
Transfected cells that were subsequently transduced with recombinant adenoviruses were  
harvested 24 hr post-transduction. Cells were washed with PBS, harvested and lysed using 
200 μl per well of Complete Lysis-M EDTA-Free Lysis Buffer (Roche Applied Science, 
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Indianapolis, USA) supplemented with protease inhibitors (Roche), at 4°C for 10 min. Cell 
debris was removed by centrifugation at 13,000 rpm for 5 min and the supernatant was 
transferred to a clean eppendorf tube. 50 μl of each cell lysate sample (in triplicate) was 
dispensed into each well of a 96 well plate. Equal volume of assay buffer containing 
chlorophenol red-β-D-galactopyranoside (CPRG) as substrate was added to each well. The 
lysates were kinetically assayed for β-gal reporter activity by measuring at 30-sec intervals 
over 60 min at
 
570 nm using SpectraMax Plus
384
 microplate reader (Molecular Devices Corp, 
Sunnyvale, CA, USA). β-gal activity of each construct was normalized against protein 
concentration determined using BCA Protein Assay Kit (Pierce Thermo Scientific, Rockford, 
IL, USA) according to the manufacturer’s protocol, as well as the respective basal β-gal 
activity to take into account the small inherent differences in β-gal activity between promoter 
constructs in the absence of p53. 
 
2.1.6 Apoptosis assay 
2 x 10
6
 HepG2 cells were electroporated with 100 μM TP53AIP1 siRNA or negative 
control siRNA (Ambion) and HBx-expressing or control plasmid (generated previously in the 
lab). Cells were subjected to UV treatment 24 hr later. The apoptosis profiles of the cells 
were analyzed by PE Annexin V and 7AAD staining according to the manufacturer’s 
protocol (BD Biosciences Pharmingen
TM
, San Deigo, CA, USA), followed by flow cytometry 
using the BD FACSCalibur
TM
 (BD Biosciences) 24 hr post-treatment. Subsequent analysis of 
the cellular profiles was performed using FlowJo software with appropriate compensation 
(Tree Star, Inc., Ashland, OR, USA). 
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2.2. RNA/DNA methodology 
2.2.1 RNA isolation and reverse transcription polymerase chain reaction 
Total RNA was prepared from cells using RNeasy® Mini Kit (Qiagen, Hilden 
Germany) according to the manufacturer’s instructions and quantified using NanoDrop™ 
1000 Spectrophotometer (Thermo Scientific). For First-strand cDNA synthesis, a 12 μl 
reaction volume comprising 1 μg of RNA, 1 μl 50 μM oligo dT primers, 1 μl 10 mM dNTP 
and RNase/nuclease free water was first heated to 65°C for 15 min and put on ice for 5 min. 
The following was then added to each tube: 4 μl 5 X First-strand buffer, 2 μl 0.1 M DTT, 1 μl 
RNase/nuclease free water and 1 μl SuperScript® II Reverse Transcriptase (Invitrogen). The 
tubes were mixed and incubated at 25°C for 5 min followed by 42°C for 60 min and 70°C for 
15 min. 
 
2.2.2 Real-time polymerase chain reaction 
Transcript abundance was determined by quantitative real-time PCR (qPCR) using 
ABI7500 Real Time PCR Detection System (Applied Biosystems™, Life Technologies™, 
Carlsbad, CA, USA). A 10 μl reaction volume was prepared comprising of 5 μl QuantiTectTM 
SYBR
®
 Green Master PCR mix (Qiagen) and 0.25 μl each of forward and reverse primers 
(Table 2). The following qPCR reaction conditions were used: an initial denaturation step at 
95°C for 10 min, followed by 45 cycles of 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 
sec. All transcript abundance was normalized against β-actin housekeeping gene.  
 
2.2.3 Mini- and maxi-preparation of plasmid DNA 
Small scale plasmid DNA preparation was performed using QIAprep
®
 Miniprep Kit 
(Qiagen) according to the manufacturer’s instructions. Large scale plasmid DNA preparation 
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was performed using NucleoBond
®
 Xtra Maxi EF kit (MACHEREY-NAGEL GmbH & Co., 
Dueren, Germany) according to the manufacturer’s instructions. 
 
2.2.4 Agarose gel electrophoresis 
DNA was mixed with 6 X DNA loading dye (0.1% bromophenol blue, 40% sucrose, 
240 mM Tris-HCL pH7.4, 60 mM EDTA-Na pH8.0) and separated on a 1% agarose gel 
prepared by dissolving agarose in 1X TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA) with 
addition of 0.5 μg/ml ethidium bromide. The gel was run using 1 X TAE buffer, at 120 volts. 
DNA bands were visualized using a UV trans-illuminator. 
 
2.2.5 DNA sequencing 
40 ng of plasmid DNA was used for ABI BigDye
®
 Terminator Cycle Sequencing 
(Applied Biosystems), with addition of the following in a 10 µl reaction volume: 2.5 µl 
BigDye Sequencing buffer, 0.5 µl 10 µM primer, 0.5 µl BigDye
®
 Terminator v3.1 and 
deionised water. Cycle sequencing was carried out in a T3000 Thermocycler (Biometra 
GmbH, Goettingen, Germany) using the following conditions: 25 cycles of 96ºC for 10 sec, 
50ºC for 10 sec, 60ºC for 4 min, then 4ºC on hold. The sequencing extension products were 
purified using ethanol precipitation. Briefly, 1 µl 250 mM EDTA, 1 µl 20 mg/ml glycogen 
and 50 µl 100% ethanol was added to each tube. Tubes were mixed well and centrifuged at 
13,000 rpm for 30 min at 4ºC. DNA pellets were subsequently washed with 50 µl 70% 
ethanol, centrifuged at 13,000 rpm (10,000 x g) for 15 min at 4ºC and dried for 3 min at 94ºC. 
DNA pellets were resuspended in 10 µl highly deionised (Hi-Di) formamide (Applied 
Biosystems) and sequenced using ABI 3100 Genetic Analyzer (Applied Biosystems). 
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2.2.6 Generation of wild-type and mutant promoter constructs 
To experimentally validate the predicted p53 response elements of the p53AIP1 gene, a 
3.8 kb fragment containing both the promoter and intron 1 p53 response elements was PCR-
amplified from genomic DNA of non-tumorous human liver tissue using Expand High 
Fidelity PCR System (Roche Applied Science) and primers 5’-
AGGAACGATGGAATCAGAGTCAC-3’ (forward) and 5’-
GCAGCAGCAAGGCACCATCATG-3’ (reverse) in a total volume of 15 μl. PCR conditions 
used are as follows: initial denaturation at 94°C for 2 min, 10 cycles of 94°C for 15 sec, 55°C 
for 30 sec and 68°C for 4 min, followed by another 10 cycles of 94°C for 30 sec, 55°C for 30 
sec and 68°C for 4 min with 5 sec cycle elongation of each successive cycle, and a final 
elongation at 72°C for 7 min. The amplified fragment was gel-purified and TA-cloned in 
front of a β-gal reporter gene (termed wild-type promoter construct). The promoter construct 
also contained the EGFP gene for visualization of transfection efficiency. In designing the 
mutant promoter and intron 1 p53 response elements, a bioinformatics approach using 
MatInspector (www.genomatix.de) transcription factor motif prediction tool was employed to 
identify mutations that abolish the response element of interest but that do not affect other 
proximal or overlapping transcription factor binding sites. The following mutant promoter 
constructs were generated: a) mutant promoter p53 response element (M1), b) mutant intron 1 
p53 response element (M2), and c) double mutant containing both mutant promoter and 
intron 1 p53 response elements (M3). The mutant promoter constructs M1, M2 and M3 were 
generated by fusion PCR using primers containing the desired mutations: 5’-
TAGaATtTCTGAAAGTTGGCAAgtgGTAAAAAGGC-3’ (forward) and 5’-
TTACcacTTGCCAACTTTCAGAaATtCTATTCCG-3’ (reverse) for mutating the promoter 
p53 response element, and 5’-CTCTaTTaCCCGGGtactTCGAGATGAAC-3’ (forward) and 
5’-CATCTCGAagtaCCCGGGtAAtAGAGGAG-3’ (reverse) for mutating the intron 1 p53 
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response element, where mutations are denoted by lower case letters. Fusion PCR conditions 
are as follows: an initial denaturation at 95°C for 15 min, followed by 20 cycles of 95°C for 
30 sec, 50°C for 30 sec and 72°C for 3 min. The amplified fragments was gel-purified and 
similarly cloned upstream of the β-gal reporter gene. All constructs were sequenced to verify 
the integrity of the DNA sequences and the successful introduction of only the desired 
mutations.  
 
2.3 Protein methodology 
2.3.1 Protein isolation from cells and quantification 
Cell pellets were lysed with 100 µl RIPA buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 
1% NP-40, 0.5% sodium Deoxycholate, 0.1% SDS) and incubated on ice for 10 min. Cells 
were sonicated using a Bioruptor
®
 (Diagenode Denville, NJ, USA) for 10 min at high setting, 
30 sec ‘on’ followed by 30 sec ‘off’. Cell debris was removed by centrifugation at 13,000 
rpm for 5 min at 4 ºC and cell lysates were transferred to new tubes.  Protein concentrations 
were determined using BCA protein assay reagent (Pierce) according to the manufacturer’s 
instructions.  
 
2.3.2 Western blotting 
20 μg of protein from each sample was mixed with 6 X loading buffer, boiled for 10 
min and subjected to gel electrophoresis on a 12% SDS poly-acrylamide gel. Following 
transfer to a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA), blots were blocked 
for 1 hr using Amersham ECL™ membrane blocking agent (GE Healthcare Biosciences, 
Uppsala, Sweden). The appropriate primary antibodies (Table 2.1) were then added to the 
blot and incubated for 1 hr: Blots were washed with PBST for 15 min and then incubated for 
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45 min with the appropriate horseradish peroxidise-conjugated secondary antibodies (Table 
2.2). Following washing, signals were detected using Amersham ECL™ Western Blotting 
Detection Reagents (GE Healthcare). The membrane was then exposed on a Kodak
®
 
BioMax™ MR film (Kodak Inc., Rochester, NY). 
 
2.3.3 Chromatin immunoprecipitation 
Protein and DNA in cells were cross-linked with 1% formaldehyde for 10 min at room 
temperature. The cross-linking reaction was quenched with 125 mM glycine for 5 min. Cells 
were washed with PBS and aliquots of 2 x 10
6
 cells were used for each chromatin 
immunoprecipitation (ChIP) assay, performed according to the manufacturer’s instructions 
(Upstate Cell Signaling Solutions, Millipore, Billerica, MA, USA). Cells were lysed using 
SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH8.0) supplemented with 
protease inhibitor cocktail (Roche) and incubated for 10 min on ice. Chromatin was sheared 
to an average size of 300 bp using a Bioruptor
®
 (Diagenode) at medium setting for 12 cycles 
and 23 cycles of 30 sec ‘on’ followed by 30 sec ‘off’ for HepG2/Hep3B and THLE-3 cells 
respectively. Cell debris was removed by centrifugation at 13,000 rpm for 10 min at 4°C and 
cell lysate was diluted using ChIP dilution buffer (0.01% SDS, 1.1% Triton X- 100, 1.2 mM 
EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl). Lysates were subsequently pre-cleared 
with 60 μl BSA-blocked protein G beads (Upstate) for 30 min at 4˚C on a rotating platform. 
A 100 μl portion of the cell lysate was saved as ‘Input DNA’. Clarified lysates were 
immunoprecipitated with 1 μg of antibody specific for the protein of interest or 1 μg normal 
mouse/rabbit IgG antibody (non-specific) overnight at 4˚C on a rotating platform. Lysates 
were then incubated with 60 μl of BSA-blocked protein G beads for 3 hr at 4˚C on a rotating 
platform. Following gentle centrifugation at 1,000 rpm for 1 min to pellet the agarose, the 
supernatant containing unbound, non-specific DNA was carefully and completely removed. 
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The agarose was subjected to a series of washing using 1 ml of buffer for 10 min at 4˚C on a 
rotating platform each time in the following order: low salt wash buffer (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.0, 150 mM NaCl); high salt wash buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH8.0, 500 mM NaCl); and 
LiCl buffer (0.25 M LiCl, 1% NP-40, 1% SDS, 1 mM EDTA, 10 mM Tris-HCl pH8.0). The 
agarose was then washed twice with 1ml of TE buffer (20 mM Tris-HCl pH8.0, 1 mM EDTA 
pH8.0) for 10 min each at room temperature on a rotating platform. Protein-DNA complexes 
were eluted twice using 250 μl of elution buffer (1%SDS, 0.1 M NaHCO3) for 15 min each 
at room temperature on a rotating platform. The combined eluates were reverse cross-linked 
using 20 μl 5 M NaCl and incubated at 65˚C, overnight. Input DNA extracted from the total 
lysate that had not been immunoprecipitated was similarly reverse cross-linked. Protein was 
removed by addition of 10 μl 0.5 M EDTA, 20 μl 1 M Tris-HCl pH 6.5 and 2 μl 10 mg/ml 
Proteinase K and incubated at 45˚C for 1 hr. Input and ChIP DNA were subsequently 
recovered by phenol/chloroform extraction and ethanol precipitation. Briefly, an equal 
volume of phenol/chloroform was added to each sample and mixed thoroughly by vortex. 
Following centrifugation at 13,000 rpm for 10 min, the aqueous phase containing DNA was 
carefully aspirated and transferred to a new tube. To increase DNA yield during precipitation 
and to visualise the DNA pellet, 20 μg of the inert carrier glycogen was added in addition to 1 
ml of 100% ethanol. Samples were incubated overnight at -20˚C. Following centrifugation at 
13,000 rpm for 30 min at 4˚C, DNA pellets were washed with 1 ml of 70% ethanol and air-
dried. All samples were resuspended in 100 μl deionised water.  
 





 Green Master PCR mix (Qiagen). Input DNA extracted 
from the total lysate that had not been immunoprecipitated but similarly reverse cross-linked 
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and recovered was used to normalize for differences in the starting amount of DNA in each 
sample. Primer sets that were designed to detect for the region of interest are listed in Table 
2.3. 
 
2.4 ChIP-on-chip and ChIP-Sequencing 
2.4.1 Sample preparation and hybridization for ChIP-on-chip  
ChIP-on-chip assays were performed on control and HBx UV-treated HepG2 cells with 
p53 DO-1 antibody (Santa Cruz Biotechnology) on NimbleGen 1.5kb promoter array 
according to the manufacturer’s recommendations. P53 ChIP and input libraries were 
prepared as follows: the ends of the p53-immunoprecipitated ChIP DNA and input DNA 
were first polished using the End-It
TM
 DNA End-Repair Kit (EPICENTRE Biotechnologies, 
Madison, WI, USA) and subsequently ligated with pre-annealed oligonucleotide linkers 
(oligo 1, 5’-GCGGTGACCCGGGAGATCTGAATTC-3’; oligo 2, 5’-GAATTCAGATC-3’). 
The linker-ligated ChIP DNA and input DNA were then amplified using the following 
conditions: annealing at 55°C for 2 min using oligo 1 as primer; extension at 72°C for 2 min 
following addition of a mixture of Taq and Pfu DNA polymerase; denaturation by heating to 
95°C for 2 min. This was followed by 22 cycles of 95°C for 1 min, 60°C for 1 min, and 72°C 
for 1 min and a final extension at 72°C for 5 min. ChIP DNA and input DNA were end-
labeled with Cy5 and Cy3 respectively, and co-hybridized to a Nimblegen ChIP-chip 
promoter tiling array (Roche NimbleGen Systems, Inc., Madison, WI, USA). The array 
contained 382,884 probes with a probe length of 50 bp and median probe space of 100 bp 
tiled 1,200 bp upstream and 300 bp downstream of 24,134 human promoters, present in 
triplicate. Post-amplification steps of ChIP and input libraries such as DNA end-labeling, co-
hybridization, and array scanning were performed by Roche NimbleGen Systems, Inc. 
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2.4.2 Bioinformatics analysis of ChIP-on-chip data 
Paired raw data files of foreground signal intensities of p53 ChIP and input libraries 
provided by Roche NimbleGen Systems, Inc were analyzed using Partek
®
 Genomics Suite™ 
6.6 (Partek Incorporated, Missouri, USA). Control or HBx differentially enriched candidate 
p53 bound regions (termed peaks) were identified based on the following criteria: (i) regions 
that contained a minimum of five consecutive probes, (ii) MAT score on fold change greater 
than 3 (HBx-enriched candidate p53 bound regions) or less than -3 (control-enriched 
candidate p53 bound regions) and (iii) p value less than 0.01, and (iv) contained putative p53 
response element(s) (binding score >60%) predicted using p53MH algorithm (Hoh et al., 
2002). Each differential candidate p53 bound region was subsequently annotated using 
Partek
®
 Genomics Suite™ 6.6 (Partek Incorporated) with the nearest gene. 
 
2.4.3 Expression microarray profiling 
Agilent Whole Human Genome Oligo Microarray (G4112A) (Agilent Technologies 
California, USA) containing 44,000 60-mer oligonucleotide probes representing 41,000 
unique human genes/transcripts, was employed for profiling of differential gene expression 
between control and HBx HepG2 UV and THLE-3 cells. RNA was isolated using MirVana
TM
 
miRNA Isolation Kit (Ambion) according to the manufacturer’s instructions. Subsequent 
cRNA generation, probe labeling and array hybridization were performed by Miltenyi 
Biotech, Cologne, Germany. Partek
®
 Genomics Suite™ was used to analyze for differential 
gene expression profiles in control and HBx cells. HBx significantly deregulated genes were 
identified based on the following criteria: (i) fold change more than 1.5 (significantly up-
regulated) or less than -1.5 (significantly down-regulated) and (ii) p value less than or equal 
to 0.05.  
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2.4.4 ChIP sample preparation for ChIP-Sequencing 
P53 ChIP-DNA from 18 high quality biological repeats were pooled together and 
prepared as a single library for Solexa Sequencing (Illumina, Inc., California, USA) at the 
Genome Sequencing Facility, National Cancer Centre Singapore. This was performed for 
both control and HBx THLE-3 cells. The ChIP library was prepared using the Illumina ChIP-
Seq Sample Preparation Kit according to the manufacturer’s recommendations. Briefly, the 
ends of the p53 DO1 antibody-immunoprecipitated ChIP DNA were polished using the End-
It
TM
 DNA end repair kit (EPICENTRE Biotechnologies). Adapters from the genomic adapter 
oligo mix were ligated to the DNA fragments following ‘A’ base addition to the 3′-ends. 
Adapter-modified DNA fragments were then amplified using Phusion DNA polymerase and 
Illumina Genomic PCR primers 1.1 and 1.2 using the following conditions: 98°C for 30 sec, 
followed by 15 cycles of 98°C for 10 sec, 65°C for 30 sec, 72°C for 30 sec and a final 
extension 72°C for 5 min. ChIP libraries were run on a 2% agarose gel and the 300 bp 
fraction of each library was gel extracted and purified. Samples were quantified using Agilent 
2100 Bioanalyzer using Agilent DNA1000 kit (Agilent Technologies). Samples were then 
sequenced using Illumina Genome Analyzer II with a standard single read 36-cycle 
sequencing protocol and Illumina’s sequencing reagents according to the manufacturer’s 
instructions (Illumina, Inc.). 
 
2.4.5 Mapping of ChIP-Seq reads, peak finding and motif search 
Raw short sequence reads (36 bp) were mapped to human reference genome hg19 
using Batman v2.0 software. A maximum of two mismatches between the read and mapping 
sites was allowed. Reads were restricted to mapping to only one unique location in the human 
genome. Control or HBx-enriched candidate p53 bound sites (or peaks) were identified using 
a peak calling software Control-based ChIP-Seq Analysis Tools (CCAT v3.0) (Tsai and 
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Chung, 2010) developed by the Genome Institute of Singapore using the default 
“transcription factor” setting. Subsequently, putative p53 response elements of the candidate 
peaks were identified using p53scan program (Benhenda et al., 2009) to scan +/-200 bp 
around peak summits. To estimate the FDR of the motif scanning program, 10,000 random 
positions in the reference genome were selected and the +/-200bp region scanned. Sites with 
a score less than the PWM score cut-off of 7% FDR were used. 
 
2.5 Methylated DNA immunopreicpitation-chip and analysis 
Methylated DNA immuoprecipitation coupled with microarray (MeDIP-chip) 
profiling was performed using a Human DNA Methylation 2.1M Deluxe Promoter Array. 
Genomic DNA was extracted from control and HBx THLE-3 cells using standard phenol-
chloroform methods. Subsequent sample preparation and array hybridization were performed 
by Arraystar Inc (Rockville, MD, USA). Essentially, genomic DNA was fragmented by 
sonication, denatured and immunoprecipitated using an antibody that binds specifically to 5-
methyl-cytosine (anti-5mC antibody). Purified immunoprecipitated methylated DNA was 
labelled with Cy5 and sonicated input DNA that was not subjected to immunoprecepitation 
was labelled with Cy3 and co-hybridized to the array. Partek
®
 Genomics Suite™ 6.6 was 
used to analyze for differential methylated sites in control versus HBx samples. Control or 
HBx significantly enriched methylated sites were identified based on the following criteria: 
(i) regions that contained a minimum of five consecutive probes and (ii) p value of less than 
0.01. 
 
2.6 p53AIP1 and HBx profiling of HCC patients 
De-identified tumour and paired non-tumorous tissues from HCC patients were 
obtained from the NCCS/SingHealth Tissue Repository with prior approval from the 
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SingHealth CIRB (2007/437/B). p53AIP1 gene expression profiles of 78 HCC patients were 
obtained by qPCR with a specific set of primers (Table 2.3). Transcript abundance of 
p53AIP1 was normalized to that of β-actin housekeeping gene. HBx status was determined 
using immunoblot analysis with HBx-specific antibody previously generated in the lab.  
 
2.7 Bioinformatics analysis of transcription factor motifs and gene functions 
Two transcription factor motif prediction tools TRANSFAC
®
 7.0 (BIOBASE GmbH, 
Wolfenbuettel, Germany) and MatInspector release 8.0.1 (www.genomatix.de) were used to 
identify sequence-specific transcription factors that bind in close proximity (±300bp) to the 
promoter and intron 1 p53 response elements. Transcription factor binding sties that were 
predicted by both prediction tools were termed high confidence transcription factor binding 
sites. The GeneMANIA software application version 2.7.13 (www.genemania.org) that uses a 
large functional association data set to predict other potential members of a query protein 
complex was employed to identify potential transcription co-regulators that associate with 
each set of predicted sequence-specific transcription factors at the promoter and intron 1 
regions but that may not bind DNA. Factors that were predicted to interact with more than 
half of the promoter/intron 1 predicted transcription factors were termed strongly-associated 
transcription co-regulators. 
 
The putative functions of significantly deregulated genes with associated p53-DNA 
binding alterations identified from expression profiling and p53 ChIP-on-chip were predicted 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID 6.7, 
http://david.abcc.ncifcrf.gov/).  
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2.8 Statistical analysis of experimental data 
Data presented were obtained from at least three independent experiments, unless 
otherwise stated. Data were expressed as mean values of experimental triplicates ± standard 
error (SE). Student’s two-sided unpaired t test was performed to analyze for statistical 
significance of differences
 
between sample means. For transcript expression analysis in 
tumour and paired non-tumorous tissues of HCC patients, data were expressed as median 
values ± SE. Student’s two-sided unpaired t test was performed to analyze for statistical 
significance of differences
 
between sample medians. 
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Chapter 3 Results 
 
3.1 HBx modulates p53-DNA binding 
3.1.1 HBx abolishes, enhances and shifts p53-DNA binding 
The viral transcription co-factor HBx disrupts host transcription regulation by 
interacting with and altering the activity of transcription factors. In this work, we are focused 
on the modulation of the central transcription regulator p53 by HBx. HBx has been 
demonstrated to interact with p53 in the nucleus, but the effect of HBx on p53 sequence-
specific binding and transcription regulation is unclear.  
 
To obtain a more comprehensive understanding of p53 modulation by HBx, we 
employed a global integrated approach to profile (i) the effect of HBx on p53-DNA binding 
by p53 chromatin immunoprecipitation coupled with microarray (p53 ChIP-on-chip), and (ii) 
the effect of HBx on gene expression by expression profiling of control and HBx HepG2 
(UV-treated) cells (Figure 3.1A). Firstly, analysis of global p53 ChIP-on-chip revealed that 
HBx altered p53 sequence-specific DNA-binding in several ways. HBx abolished p53 
binding to candidate p53 response elements of 98 genes (Figure 3.1B); HBx enhanced p53 
binding to the candidate p53 response elements of 113 genes (Figure 3.1B); and strikingly, 
HBx also induced a novel shift in p53-DNA occupancy - simultaneously alleviating and 
enhancing p53 binding - to distinct candidate p53 response elements at the promoters of 21 
genes (Figure 3.1B). An example of each HBx-altered p53-DNA binding pattern 
(abolishment, enhancement and shift) at the promoter of a representative gene is illustrated in 
Figures 3.1 C, D and E respectively.  
 


































































Figure 3.1 HBx alters p53-DNA binding. A Illustration of our strategy using a combination of ChIP-on-chip and expression profiling of UV-
treated HepG2 cells transduced with recombinant HBx or control vectors. B. Patterns of p53-DNA binding alterations by HBx from p53 ChIP-
on-chip analysis. Numbers within brackets refer to the number of genes with the respective p53-DNA binding alteration. C, D and E. Graphical 
representation of examples of abolished (C), enhanced (D) and shift (E) in p53-DNA binding by HBx. Figure was generated using SignalMap 
software (NimbleGen Systems). 
E D C 
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This is the first report to show that HBx alters p53 sequence-specific DNA binding 
globally. Importantly, the findings suggest that HBx can alter p53-DNA binding in opposing 
ways (abolish as well as enhance p53-DNA binding), arguing for a more complex mechanism 
of p53 modulation by the viral protein than previously proposed. 
 
3.1.2 HBx-altered p53-DNA binding is associated with gene deregulation 
Secondly, to examine the biological significance of these observed p53-DNA binding 
alterations, microarray-based gene expression profiles were integrated with p53 ChIP-on-chip 
data (Figure 3.2A). As shown in Figure 3.2B, only a third of genes (32.8%) with HBx-altered 
p53-DNA binding at their promoters exhibited significantly deregulated expression (fold 
change >1.5 or <-1.5, p≤0.05). The majority of genes (67.2%) with HBx-altered p53-DNA 
binding at their promoters were not significantly deregulated by HBx (Figure 3.2B). This 
finding was not surprising as it is known that not all transcription factor-DNA binding events 
affect gene transcription (Wei et al, 2006). Nevertheless, of particular importance was the 
subset of HBx-altered p53-DNA binding that was associated with significantly deregulated 
corresponding gene expression. To examine the potential functions of these HBx-deregulated 
genes, the genes were queried using DAVID, a bioinformatics resource that predicts the most 
enriched Gene Ontology (GO) terms. Notably, the HBx-deregulated genes with altered p53-
DNA binding were predicted to be involved in cell cycle, metabolism, protein localization, 
apoptosis, cellular response, DNA repair and transcription (Figure 3.2C). This suggests that 
modulation of p53 by HBx potentially disrupts the regulation of such key cellular processes 
that plausibly contributes to neoplastic transformation.  
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Figure 3.2 A subset of HBx-altered p53-DNA binding is associated with corresponding 
gene deregulation. A. Illustration of integrated p53 ChIP-on-chip and expression profiling to 
identify potentially functional HBx-altered p53-DNA binding (indicate by the arrow). B. 
Graphical representation HBx-altered p53-DNA binding associated with corresponding gene 
deregulation. Data is presented in percentages that are indicated in brackets. C. Gene 
Ontology (GO) term enrichment for significantly deregulated genes with associated p53-
DNA binding alteration using DAVID, presented in order of decreasing significance –log(P 
value). 
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Next, we proceeded to examine the specific gene deregulation patterns that were 
linked to each type of p53-DNA binding alteration by HBx. Interestingly, each type of p53-
DNA binding alteration (abolishment, enhancement or shift) did not correspond with any 
gene deregulation pattern (up- or down-regulation) (Figure 3.3A). Specifically, 
approximately equal numbers of genes were significantly up-regulated (indicated by red 
segment) or down-regulated (indicated by green segment) in each category of HBx-altered 
p53-DNA binding (Figure 3.3A). For example, 17% of genes with abolished p53-DNA 
binding at their promoter regions were significantly up-regulated, while a comparable 
proportion of genes (18%) were significantly down-regulated (Figure 3.3A). Using 
representative deregulated genes selected from each category of altered p53 binding, we 
experimentally validated the HBx-altered p53-DNA binding and gene deregulation patterns 
by ChIP-qPCR and qRT-PCR respectively (Figure 3.3B). Indeed, the abolishment, 
enhancement or shift in p53-DNA binding by HBx did not associate with any particular type 
of gene deregulation pattern. For example, HBx-enhanced p53 binding at the promoters of 
FAS and ABCD2 were associated with increased gene expression, while HBx-enhanced p53 
binding at the promoters of AKT1S1 and GDNF were conversely associated with decreased 
gene expression (Figure 3.3B). Similarly, HBx-abolished p53 binding at the promoters of 
p53AIP1 and SPINK6 were linked to their up-regulation, while HBx-abolished p53 binding at 
the promoter of DUX4 was conversely linked to its down-regulation. Taken together, the 
findings further support a complex mechanism of p53 modulation by the viral X protein.  
 
While it is possible that the observed deregulated gene expression patterns could also 
be the result of the disruption of other modes of post-transcriptional regulation such as 
regulation by microRNAs and non-coding RNAs as well as the stability, intracellular  




















1 P53AIP1 -15.17 1.66 0.05
2 SPINK6 -9.12 3.10 0.01
3 DUX4 -4.98 -1.50 0.00
4 ERCC2 -14.42 1.01 0.97
5 C1D -12.10 1.00 0.92
6 FAS 7.20 2.11 0.00
7 ABCD2 6.30 1.62 0.04
8 AKT1S1 6.00 -2.51 0.00
9 GDNF 4.00 -1.44 0.00
10 HNF4 10.60 1.18 0.91































Figure 3.3. HBx-altered p53-DNA binding does not associate with any gene deregulation 
pattern. A. Graphical representation of HBx-altered p53-DNA binding patterns (abolished, 
enhanced, shift) with associated gene expression patterns (up-regulated, down-regulated and 
unchanged). Gene deregulation patterns associated with each p53-DNA binding alteration are 
presented in percentages. B. ChIP-qPCR and qRT-PCR validated p53-DNA binding 
alterations with corresponding gene deregulation by HBx. Shown are the gene name, ChIP-
on-chip p53 binding pattern and MAT score, as well as corresponding gene expression fold 
change and p value. Significantly deregulated candidate genes (fold change >1.5 or <-1.5, p 
value ≤ 0.05) with altered p53 binding are indicated in bold.  
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localization and transport of mRNA by HBx, disruption of p53-mediated transcription 
primarily accounts for the gene deregulation patterns since HBx functions predominantly as a 
transcription co-factor in transcription regulation. Further, since mammalian gene 
transcription regulation is typically the result of an intricate interplay of transcription factors 
and co-regulators, these findings instead suggest that other transcription factors/co-regulators 
may co-operate with p53 to determine the resultant gene deregulation patterns.  
 
Thus, to examine the role of HBx in modulating p53-DNA binding and transcription 
regulation in greater detail, p53AIP1 – an experimentally validated HBx-deregulated gene 
with associated altered p53 binding at its promoter region identified from the global p53 
ChIP-on-chip and expression profiling studies was selected for further characterization 
(Figure 3.3B). P53AIP1 was selected for several reasons: it is a known p53-regulated gene, 
and its pro-apoptotic function is consistent with the reported role of HBx in apoptosis 
induction as well as with the predicted function of HBx-deregulated genes in positively 
regulating apoptosis (Figure 3.2C). 
 
3.2 HBx induces a novel shift in p53 binding to the regulatory region of p53AIP1 
3.2.1 HBx abolishes p53 recruitment to a novel p53AIP1 promoter p53 response element 
From the integrated global p53-DNA binding and expression profiling study of 
control and HBx HepG2 (UV-treated) cells, we identified a known p53-regulated gene 
p53AIP1 that was deregulated by HBx with associated altered p53 binding at its promoter 
region. From the p53 ChIP-on-chip study, p53 bound to the promoter region of p53AIP1 gene 
in control cells, and this binding was abolished in the presence of HBx. Figure 3.4A shows 
the novel p53 binding region indicated by a peak spanning 241 bp and comprising of signals 
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from five consecutive microarray probes. This candidate p53 binding region was further 
predicted to contain a p53 response element using the p53MH algorithm (Figure 3.4A). 
Located 861 bp upstream of the p53AIP1 transcription start site, this previously unreported 
promoter p53 response element consisted of two half-sites separated by a 9 bp spacer and 
exhibited 65% similarity to the p53 consensus sequence as predicted by p53MH (Figure 
3.4A).  
 
To experimentally validate this observed HBx-induced differential binding of p53, 
ChIP using p53-specific antibody or normal IgG (non-specific control) was performed on 
control and HBx HepG2 (UV-treated) cells and ChIP DNA enrichment was determined by 
quantitative real-time PCR (qPCR) with primers specific for detection of the promoter region 
of interest (Table 2.3). Consistent with the p53 ChIP-on-chip results, significant enrichment 
of the promoter region was detected in control cells following p53 ChIP (p<0.01), but not in 
p53 ChIP of HBx cells and cells immunoprecipitated with the non-specific IgG antibody 
(Figure 3.4Bi). This confirmed that p53 bound to the promoter region of p53AIP1 and this 
binding is abolished in the presence of HBx.  
 
To examine if this HBx-induced differential p53 binding at the p53AIP1 promoter 
was specific to the DNA-damaging treatment (UV) applied or the cell line used (transformed 
HepG2 liver cells), ChIP using p53-specific antibody or normal IgG was similarly performed 
on control and HBx-expressing non-transformed THLE-3 liver cells without DNA damaging 
treatment. Consistent with the observations in UV-treated HepG2 cells, p53 bound to the 
promoter region in control THLE-3 cells, and this binding was significantly reduced in the  
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Figure 3.4. HBx abolishes p53 binding at a novel response element in p53AIP1 
promoter. A. A novel p53 RE in the promoter region of p53AIP1 gene is identified by ChIP-
on-chip experiments. The DNA sequence of the novel p53 RE is 65% similar to the p53 
consensus sequence. Nucleotides in capital letters represent identity of genomic sequence to 
the consensus; nucleotides in lower case letters represent disparity with the consensus. Figure 
was generated using SignalMap software (NimbleGen Systems). p53 binding at the novel p53 
RE is abolished in the presence of HBx, indicated by the absence of a peak in HBx-p53 ChIP 
sample. B. Differential p53 binding at the novel p53 RE is successfully validated by ChIP-
qPCR. p53 ChIP performed on control and HBx (i) HepG2 (UV-treated) and (ii) THLE-3 
cells. All error bars show standard error of the mean (± SEM) of triplicate experiments.  
IgG IgG 
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presence of HBx (p<0.01) (Figure 3.4Bii). The data thus suggests that HBx abolishes p53 
binding to the p53AIP1 promoter response element regardless of treatment or cell line used. 
 
3.2.2 HBx enhances p53 binding to a previously reported p53AIP1 intron 1 p53 response 
element 
A functional p53 response element located in intron 1 of p53AIP1 was previously 
reported by Oda et al. to be necessary for its p53-mediated regulation (Figure 3.5A). As the 
intron 1 p53 response element is located approximately 2 kb downstream of the p53AIP1 
transcription start site, it was not examined by the p53 ChIP-on-chip screen that probed only 
a 1.5 kb promoter region of each gene. A comparison of the intron 1 and promoter p53 
response elements showed that the intron 1 response element exhibited a higher degree of 
similarity to the p53 consensus sequence (80% similarity as predicted by p53MH), as 
compared to the promoter response element (65% similarity) (Figure 3.5B). Another feature 
that distinguished the intron 1 from the promoter p53 response element is the absence of a 
spacer in the intron 1 response element where the two p53 half-sites occur in tandem (Figure 
3.5B). As differences in the base and spacer composition of p53 response elements are 
thought to influence p53 binding and subsequent transcription regulation, we therefore 
examined the pattern of p53 binding at this intron 1 p53 response element and if HBx also 
affected this binding. 
 
To this end, ChIP using p53-specific antibody or normal IgG was performed on 
control and HBx-expressing HepG2 (UV-treated) cells as well as THLE-3 cells and ChIP 
DNA enrichment was determined using qPCR with primers specific for detection of the 
intron 1 region (Table 2.3). Intriguingly, binding of p53 to the intron 1 response element was 
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significantly enhanced in the presence of HBx in both cell lines tested (p<0.05) and 
regardless of UV treatment applied (Figure 3.5Ci and ii). Further, since HBx is known to bind 
DNA indirectly via transcription factors such as p53, we asked if HBx was also recruited 
together with p53 to the intron 1 region of p53AIP1. ChIP using a HBx-specific antibody 
generated in our lab was performed on control and HBx-expressing HepG2 (UV-treated) and 
THLE-3 cells, and ChIP DNA enrichment was similarly determined using qPCR with 
primers specific for detection of the intron 1 region. Analysis of HBx ChIP-qPCR revealed 
significant enrichment of the intron 1 region in the presence of HBx (p<0.05), indicating that 
a HBx-p53 transcription complex may be recruited to the intron 1 RE (Figure 3.5Di and ii). 
Taken together, our findings suggest that HBx might directly induce a novel shift in p53 
recruitment from the promoter to the intron 1 response element of p53AIP1 gene. 
 
3.2.3 The novel p53AIP1 promoter p53 response element identified is essential for p53-
mediated transcription  
To determine if the previously unreported p53AIP1 promoter p53 response element 
identified in our p53 ChIP-on-chip study is a bona fide p53 response element, a DNA 
fragment harbouring the promoter p53 response element was cloned upstream of a beta-
galactosidase (β-gal) reporter gene and assayed for reporter activity in p53-deficient Hep3B 
cells. Hep3B cells were used as the effect of exogenously introduced p53 could be 
consistently and easily tested. Approximately 80% transfection efficiency in Hep3B cells was 
consistently achieved in all our reporter assays as shown by the proportion of green 
fluorescence cells detected following chemical transfection of reporter constructs harbouring 
the enhanced green fluorescence protein (EGFP) gene (Figure 3.6A). In the absence of p53, 
almost no reporter activity was detected (Figure 3.6B). However in the presence of p53, 
reporter activity increased 6-fold compared to that sans p53 (p<0.01) (Figure 3.6B). 












Reported intron 1 
p53 RE
B p53 RE Motif % similarity to consensus
Promoter tAGtATGTCT GAAAGTTGG cAACATGTaa 65










Figure 3.5. HBx enhances p53 binding to the known intron 1 response element of 
p53AIP1. A. Illustration of p53 RE positions relative to p53AIP1 gene. Each p53 RE is 
depicted as two black boxes, each representing one half-site of the p53 consensus sequence. 
The transcription start site (+1) and translation start site (ATG) of p53AIP1 gene are also 
depicted. B. Comparison of promoter and intron 1 p53 response elements. Shown are the 
motifs and similarity to the consensus sequence. C. p53 binding at intron 1 p53 RE is 
enhanced in the presence of HBx. p53 ChIP-qPCR was performed on control and HBx (i) 
HepG2 (UV-treated) and (ii) THLE-3 cells. ChIP using normal IgG was performed as a non-
specific control. D. HBx indirectly binds to intron 1 p53 RE of p53AIP1. HBx ChIP-qPCR 
was performed on control and HBx (i) HepG2 (UV-treated) and (ii) THLE-3 cells using 
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Moreover, depletion of p53 using short-interfering RNA (siRNA) specific for p53 negated 
the increase in reporter activity (p<0.01), indicating that the p53AIP1 regulatory region tested 
that contained the promoter p53 response element is responsive to p53 (Figure 3.6B).  
 
To confirm that the novel p53AIP1 promoter p53 response element is indeed 
functional and essential for transcription regulation, core nucleotides of the p53 response 
element that are crucial for p53-DNA binding were mutated, inserted upstream of the β-gal 
reporter gene and assayed for reporter activity. In addition, reporter constructs harbouring 
mutated intron 1 p53 response element (M2) as well as a combination of mutated promoter 
and intron 1 p53 response elements (double mutant M3) were generated and similarly 
assayed. All mutations introduced were confirmed not to obliterate or create other 
overlapping transcription factor binding sites (TFBS) by comparing TFBS profiles of wild-
type and mutant promoters using the transcription factor binding motif prediction tool 
MatInspector. Consistent with previous reports that the intron 1 p53 response element of 
p53AIP1 is functional and essential for transcription, only marginal reporter activity was 
observed when the intron 1 p53 response element was mutated (M2 construct) as compared to 
that of the construct harbouring wild-type p53 response elements (p<0.05) (Figure 3.6C). 
Importantly, a complete loss in reporter activity was observed by mutating the promoter p53 
response element (M1 construct) (p<0.01) (Figure 3.6C), demonstrating that the promoter 
p53 response element is indeed a bona fide p53 response element and essential for 
transcription stimulation. The construct harbouring both mutated promoter and intron 1 p53 
response elements (M3) unexpectedly exhibited higher reporter activity than the individual 
mutants, but this activity was still markedly lower than that of the wild-type promoter (Figure 
3.6C). We speculate that this may be due to the action of other transcription regulators that 
may bind to the examined promoter region, though their role in transcription activation may  

























Figure 3.6. Both promoter and intron 1 p53 response elements are functional and 
necessary for p53AIP1 regulation. A. High transfection efficiency (approximately 80%) is 
consistently achieved in Hep3B cells. Shown are the dark field and the corresponding 
superimposed image of a representative transfection experiment using the EGFP-bearing 
promoter construct in Hep3B cells. B. p53 stimulates p53AIP1 promoter activity. p53-
deficient Hep3B cells were co-transfected with wild-type promoter construct and indicated 
plasmids and/or siRNA, and assayed for β-gal activity. p53 and EGFP expression levels are 
examined by western blotting. C. Both p53 REs are functional and necessary for p53AIP1 
regulation. Hep3B cells were co-transfected with wild-type or mutant promoter constructs, 
and p53 or control plasmid. Basal β-gal activity is denoted by the vertical black dashed line. 
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be of a lesser extent as compared to the central role of p53. Collectively, the data provides 
strong evidence that the novel promoter p53 response element of p53AIP1 identified from the 
p53 ChIP-on-chip study is functional and essential for p53-mediated transcription. 
 
3.3 HBx modulation of p53-DNA binding deregulates p53AIP1 expression  
3.3.1 HBx increases p53AIP1 expression  
Having successfully validated that HBx induces a novel shift in p53-DNA binding at 
the regulatory region of p53AIP1, we next investigated if this HBx-altered p53-DNA binding 
affects p53AIP1 expression. As shown in Figure 3.2B, integration of p53 ChIP-on-chip and 
expression profiling of control and HBx UV-treated HepG2 cells revealed that the HBx-
induced differential p53 binding at the p53AIP1 regulatory region was associated with a 1.6-
fold increase in p53AIP1 expression. To experimentally validate the expression array data, 
p53AIP1 expression was measured in control and HBx HepG2 (UV-treated) and THLE-3 
cells using qRT-PCR. Consistent with the expression array results, p53AIP1 expression 
increased 2-fold (p<0.05) and 1.6-fold (p<0.01) in HBx HepG2 (UV-treated) and HBx 
THLE-3 cells respectively, compared to the respective control cells (Figure 3.7Ai and ii).  
 
To determine if this increase in p53AIP1 expression by HBx is mediated by p53, 
siRNA specific for p53 or negative control siRNA was introduced into both HepG2 (UV-
treated) and THLE-3 cells and cells were subsequently transduced with control or HBx 
vectors. As shown in Figures 3.7Bi and ii, transient depletion of p53 using p53-specific 
siRNA abrogated the increase in p53AIP1 expression by HBx in both of the cell lines tested. 
These findings strongly suggest that HBx increases p53AIP1 expression through p53.  
 






















































































































































































































































Figure 3.7. HBx up-regulates p53AIP1 in a p53-dependent manner. A. p53AIP1 
expression increases in the presence of HBx. (i) HepG2 (UV-treated) and (ii) THLE-3 cells 
were transduced with recombinant HBx and control vectors. p53AIP1 expression levels were 
measured by qRT-PCR and normalized against beta-actin. B. (i) HepG2 (UV-treated) and (ii) 
THLE-3 cells were transfected with p53-specific or control siRNA, and transduced with HBx 
or control vectors 24 h post-transfection. p53AIP1 expression levels were measured by qRT-
PCR and normalized against beta-actin. All error bars show ± SEM of triplicate experiments. 
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3.3.2 A shift in p53-DNA binding is essential for HBx-induced increase in adjacent gene 
expression  
Our data thus far suggests that HBx induces a novel shift in p53 binding from the 
promoter to intron 1 response element of p53AIP1 gene, and that p53 mediates HBx-induced 
increase in p53AIP1 expression. To determine if the shift in p53-DNA binding is essential for 
the increased gene expression by HBx, reporter activities of the wild-type (WT), promoter 
(M1) and intron 1 (M2) p53 response element single mutants as well as the double mutant 
(M3) were assayed for β-gal reporter activity in the presence or absence of HBx. Consistent 
with the findings that HBx increases p53AIP1 expression, HBx increased reporter activity of 
the WT construct that harboured intact p53 response elements by approximately 1.4-fold 
(p<0.01) (Figure 3.8). Next, we used the construct bearing the mutated promoter p53 
response element (M1) to recapitulate the shift in p53 binding to the intron 1 p53 response 
element and examined the effect of HBx on its reporter activity. Importantly, HBx increased 
M1 reporter activity by approximately 1.8-fold (p<0.01) (Figure 3.8). This increase in M1 
promoter activity by HBx was significantly greater than that of the WT construct (p<0.05). In 
contrast, reporter activities of constructs containing the mutated intron 1 p53 response 
element (M2 and double mutant M3) were not significantly enhanced in the presence of HBx 
(Figure 3.8), demonstrating that the shift in p53 binding from the promoter to intron 1 
response element of p53AIP1 is essential for stimulation of adjacent gene expression by HBx. 
These findings also hint that HBx might relieve p53-associated repression at the promoter 
region and enhance p53-associated transcription stimulation at the intron 1 region of 
p53AIP1.  
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3.3.3 Increased p53AIP1 expression in tumours of HCC patients with high HBx 
expression 
To evaluate the clinical relevance of the in vitro findings that HBx increases p53AIP1 
expression, p53AIP1 gene expression and HBx protein expression profiles were analyzed in 
78 de-identified tumour (T) and paired non-tumorous (NT) tissues of HCC patients obtained 
from the NCCS/SingHealth Tissue Repository. p53AIP1 expression was determined using 
qRT-PCR analysis and normalized to the respective β-actin expression. HBx protein 
expression was determined using western blotting with a HBx-specific antibody generated in 
our lab followed by quantification using densitometry analysis. HBx expression of each 
sample was normalized to the respective β-actin expression. Patients were subsequently 
classified into two groups according to their HBx status. Thirty-two HCC patients were 
classified in ‘high HBx status’ group where HBx expression is more than 2-fold T versus NT 
while 46 HCC patients were classified in ‘low HBx status’ group where HBx expression is 
less than 2-fold T versus NT. Strikingly, a comparison of the ratio of p53AIP1 expression 
(T/NT) and HBx status of the 78 HCC patients showed significantly higher (p<0.05) 
p53AIP1 expression in HCC patients with high HBx status (median 1.46) in contrast to that 
of HCC patients with low HBx status (median -1.36) (Figure 3.9). This finding lends clinical 
relevance to our in vitro observations thus far that HBx increases p53AIP1 expression. 
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Figure 3.8. HBx stimulates target gene expression in promoter assay. Hep3B cells were 
co-transfected with wild-type or mutant promoter constructs, and p53 or control plasmid. 
Cells were transduced with HBx or control adenovirus 24 h post-transfection. All error bars 













Figure 3.9. p53AIP1 gene expression is significantly higher in HCC patients with high 
HBx protein expression. Gene expression profiles and HBx protein status of tumour (T) and 
adjacent non-tumorous (NT) samples of 78 HCC patients were obtained and analyzed for 
association. The median ratio of p53AIP1 gene expression (T/NT) in 32 patients with low 
HBx protein expression (T/NT<2) and 46 patients with high HBx protein expression 
(T/NT>2) is -1.36 and 1.46 respectively (p=0.014).  
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3.3.4 Increased p53AIP1 expression mediates HBx-induced apoptosis 
Having demonstrated that HBx induces p53AIP1 expression, we next examined the 
functional relevance of this deregulation. Our lab had previously reported that HBx sensitizes 
UV-treated HepG2 cells to apoptosis (Lee et al., 2005b). Therefore, we hypothesized that the 
apoptosis-inducing protein p53AIP1 may be a potential mediator of HBx-induced apoptosis. 
To this end, HepG2 cells were treated with control or HBx vectors as well as control or 
p53AIP1-specific siRNA, treated with UV irradiation and analyzed for their apoptosis 
profiles by detection of phosphatidylserine externalization through staining with Annexin V 
and membrane integrity via the exclusion of 7AAD. A 70% reduction in p53AIP1 expression 
was consistently achieved using p53AIP1-specific siRNA (Figure 3.10A). In agreement with 
our lab’s previous study, the population of apoptotic cells increased to approximately 20% in 
the presence of HBx compared to 12% in control cells (p<0.01) (Figures 3.10B and C). This 
increase was abrogated by transiently depleting p53AIP1 using p53AIP1-specific siRNA 
(p<0.01) (Figure 3.10B, C), suggesting a role for p53AIP1 in HBx-induced apoptosis, 
possibly via a p53-dependent mechanism. 
 
3.4. HBx alters co-regulator recruitment and specific p53 post-translational 
modification 
3.4.1 HBx does not alter p53 phosphorylation at serine 46 
p53 has been reported to be regulated by a myriad of site-specific post-translational 
modifications including phosphorylation, acetylation, ubiquitination and sumoylation. It is 
proposed that these post-translational modifications can change the conformation of the p53 
protein, thereby altering its DNA-binding affinity or sequence-specific selectivity. 
Importantly, the site-specific phosphorylation at p53 serine 46 (Ser46) was previously 





































































Figure 3.10. p53AIP1 depletion abrogates HBx-induced apoptosis. A. Transient knock-down of p53AIP1 using RNA interference. p53AIP1-
specific and control siRNA was introduced into HepG2 cells using electroporation and cells were harvested 48 h post-transfection. A reduction 
in p53AIP1 mRNA levels was achieved in cells with p53AIP1-specific siRNA compared to that with control siRNA as measured by RT-qPCR. 
Shown are p53AIP1 and beta-actin expression levels analyzed by agarose gel electrophoresis. B, C. Increased apoptosis of HBx cells is negated 
by p53AIP1 knockdown. HepG2 cells were co-transfected with HBx or control vectors and p53AIP1-specific or control siRNA. Apoptosis 
profiles of cells were determined using PE Annexin V and 7AAD staining, followed by flow cytometry detection and analysis. B. Shown are the 
staining profiles of a representative set of experiments. The apoptotic cell population is indicated in the upper left quadrant (Annexin V positive, 
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reported by Oda et al. to correlate with p53AIP1 expression and apoptosis induction. We 
therefore hypothesized that HBx might enhance phosphorylation of p53 Ser46, altering its 
DNA-binding affinity and resulting in increased p53AIP1 expression.  
 
To test this hypothesis, phosphorylation levels of p53 Ser46 were examined in control 
and HBx HepG2 (UV-treated) and THLE-3 cells over a 72 hr time period, using an antibody 
specific for phosphorylated p53 Ser46. As shown in Figure 3.11, similar phosphorylation 
levels of p53 Ser46 were observed in control and HBx cells at each time point, and remained 
unchanged over the course of 72 hr. These observations were consistent regardless of 
treatment by UV irradiation or cell line used (Figure 3.11). Since p53 Ser46 phosphorylation 
is unaffected by HBx, this site-specific p53 post-translational modification is thus unlikely to 
be involved in HBx-induced p53AIP1 deregulation. 
 
3.4.2 HBx perturbs unique p53-associated transcription co-regulators 
3.4.2.1 DNA-bound p53 co-regulators  
Mammalian gene regulation typically involves the interplay of multiple sequence-
specific transcription factors and/or co-regulators that bind to transcription factors 
(collectively termed co-regulatory module). As our findings also thus far hint at the possible 
involvement of other p53-associated transcription factors/co-regulators that might influence 
trans-activation or trans-repression of p53AIP1 expression, we hypothesized that HBx may 
modulate p53 binding/transcription regulation depending on the specific combination of the 
surrounding associated transcription factors/co-regulators at the promoter and intron 1 region 
of p53AIP1.  
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Figure 3.11. HBx does not induce phosphorylation of p53 at Serine 46. Phosphorylation 
levels of p53 serine 46 residue (Ser46) are unchanged in HBx cells. HepG2 (UV-treated) and 
THLE-3 cells were transduced with recombinant HBx (H) or control (C) vectors and 
harvested at various time points. Immunoblot detection of p53 Ser46 phosphorylation levels 
in (i) HepG2 (UV-treated) and (ii) THLE-3 cells was performed using an antibody specific 
for the phosphorylated residue.  
Chapter 3 Results 
79 
 
To identify potential proximal transcription factors at the promoter and intron 1 regions, 
a computational approach was employed to predict for transcription factor motifs in close 
proximity (±300 bp) to the p53 response element in both regions (Figure 3.12A). Five high 
confidence transcription factor motifs were predicted by both TRANSFAC and MatInspector 
transcription factor binding site prediction tools to reside adjacent to the promoter p53 
response element (Figure 3.12Bi). These are heat shock transcription factor 1 (HSF1), globin 
transcription factor 1 (GATA-1), Yin Yang 1 (YY1), myeloid zinc finger 1 (MZF1) and 
transcription factor CP2 (Figure 3.12B). At the intron 1 region, four high confidence 
transcription factor motifs were predicted, namely transcription factor PU.1/SPI1, specificity 
protein 1 (Sp1), ets variant gene 4 (ETV4/PEA3) and aryl hydrocarbon receptor (AHR) 
(Figure 3.12Bii).  
 
To further select for strong p53-interacting candidates, these predicted high 
confidence transcription factors were then searched in the literature for known interactions 
with p53. Notably, only transcription repressors YY1 and GATA-1 located -102 bp and -175 
bp respectively relative to the promoter p53 response element, and transcription activator Sp1 
located -145 bp relative to the intron 1 p53 response element were shortlisted as strong p53-
interacting candidates (Figure 3.12B and 3.13A). To assess if these strong p53-interacting 
candidates were recruited to their respective response elements and if HBx affected their 
binding, ChIP was performed on control and HBx THLE-3 cells using antibodies specific for 
YY1, GATA-1 and Sp1. Similar to the pattern of p53 binding at the promoter response 
element, YY1 and GATA-1 bound to their respective predicted binding sites in control cells 
but this binding was abolished in the presence of HBx (p<0.05 and p<0.01 respectively) 
(Figure 3.13B and C). There was no significant ChIP enrichment in both control and HBx  
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Figure 3.12. High confidence transcription factor binding motifs adjacent to promoter 
and intron 1 p53 response elements predicted by both TRANSFAC and MatInspector. 
A. DNA sequence ±300 bp of each p53 response element was queried for transcription factor 
binding motifs using MatInspector and TRANSFAC prediction tools. B. Shown are the 
predicted high confidence transcription factors and their respective motif positions relative to 
the (i) promoter and (ii) intron 1 p53 response element that were predicted by both 
































































































































































































Figure 3.13. HBx perturbs recruitment of distinct transcription co-regulators. A. 
MatInspector- and TRANSFAC-predicted high confidence transcription factor binding motifs 
(TFBS) adjacent to the p53 REs (±300 bp) that interact with p53. Shown are their positions 
relative to the respective p53 RE. B, C and D. Differential binding of transcription factors 
YY1, GATA-1 and Sp1 in the presence of HBx were validated using ChIP-qPCR on control 
and HBx THLE-3 cells using specific antibodies for YY1 (B), GATA-1 (C) and Sp1 (D). 
ChIP using normal IgG was performed as a non-specific control. All error bars show ± SEM 
of triplicate experiments. 
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cells at the intron 1 region where no YY1 or GATA-1 motifs were predicted (Figure 3.13B 
and C). On the other hand, Sp1 binding to its predicted response element was enhanced in the 
presence of HBx, analogous to that of p53 at the intron 1 RE (p<0.01) (Figure 3.13D). There 
was no significant ChIP enrichment in both control and HBx cells at the promoter region 
where no Sp1 motif was predicted (Figure 3.13D). These findings suggest that HBx disrupts 
the recruitment of a transcriptionally repressive p53-YY1-GATA1 complex and favours the 
recruitment of a transcriptionally activating p53-Sp1 complex to the regulatory region of 
p53AIP1. 
 
3.4.2.2 p53-associated transcription factors modulate gene transcription 
To examine if the recruitment of the p53-associated transcription factors YY1, 
GATA-1 and Sp1 modulate p53AIP1 transcription, each transcription factor of interest was 
depleted using the respective specific siRNA and its effect on p53AIP1 expression was 
determined. In addition, a complementary two-pronged approach using RNA interference and 
mutagenesis studies in the aforementioned reporter assay system was also employed. 
Essentially, the transcription factor of interest was either depleted using siRNA or prevented 
to bind to their respective binding site in the p53AIP1 regulatory region by mutating the core 
nucleotides of the response element, and assayed for β-gal reporter activity in Hep3B cells.  
 
 First, by chemically transfecting siRNA specific for transcription repressors YY1 and 
GATA-1 into cells, efficient knockdown in their respective expression was achieved (Figure 
3.14Ai and ii). qRT-PCR analysis of p53AIP1 expression levels in THLE-3 cells revealed 
that depletion of either YY1 or GATA-1 resulted in a significant increase in p53AIP1 
expression as compared to that treated with the negative control siRNA (p<0.01) (Figure 
3.14B). Moreover, analysis of the reporter activity of wild-type p53AIP1 promoter construct 
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in YY1- and GATA-1- depleted Hep3B cells showed a moderate increase in reporter activity 
in the presence of p53 (p<0.05) (Figure 3.14C). To test if this increase in gene transcription is 
indeed a result of decreased transcription factor recruitment, and not due to unanticipated off-
target effects of the siRNAs used, we employed the second approach that specifically 
examines the effect of abolishing transcription factor recruitment to the binding site of 
interest by mutating the response element. Significantly, abolishment of YY1 or GATA-1 
binding to their respective response elements by mutagenesis studies showed enhanced 
reporter activity of the p53AIP1 promoter (p<0.05 and p<0.01 respectively) (Figure 3.14D), 
confirming that the transcription repressors YY1 and GATA-1 negatively modulate p53AIP1 
expression. 
 
To examine if Sp1 recruitment to p53AIP1 intron 1 region influences p53AIP1 
expression in the presence of HBx, Sp1-specific RNA interference and mutagenesis studies 
were similarly performed in the presence or absence of HBx. Following efficient knockdown 
of Sp1 in THLE-3 cells (Figure 3.15A), qRT-PCR analysis of p53AIP1 expression revealed 
that Sp1 depletion negated the increase in p53AIP1 expression by HBx (Figure 3.15B). In 
addition, transient depletion of Sp1 using Sp1-specific siRNA moderately blunted the 
increase in reporter activity in HBx cells, albeit not as pronounced as that observed in Sp1-
depleted THLE-3 cells (Figure 3.15C). Consistently, obliteration of Sp1 binding to the 
p53AIP1 intron 1 region by mutating its response element also moderately blunted the HBx-
induced increase in reporter activity (Figure 3.15D). We speculate that over-expression of 
p53 by exogenously introducing p53 into Hep3B cells in the reporter assays might have some 
compensatory effects that may mask the effect of Sp1 depletion on reporter activity. This 
might account for the modest effect in reporter activity observed in Sp1-depleted HBx cells  
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Figure 3.14. YY1 and GATA-1 negatively modulate p53AIP1 expression. A. Efficient 
knockdown of (i) YY1 and (ii) GATA-1 is achieved using the respective specific siRNAs. 
Shown are western blots of YY1, GATA-1 and loading control GAPDH of THLE-3 cells 
transfected with the indicated siRNAs. B and C. Knockdown of YY1 and GATA-1 using 
specific siRNAs increases gene expression. B. THLE-3 cells were transfected with YY1, 
GATA-1 or control scrambled siRNA. P53AIP1 expression was measured using qRT-PCR. 
C. Hep3B cells were co-transfected with wild-type p53AIP1 promoter construct, p53 or 
control plasmid and YY1, GATA-1 or control scrambled siRNA, and assayed for β-gal 
activity. D. Mutation of YY1 and GATA-1 binding sites increases gene expression. Hep3B 
cells were co-transfected with wild-type, YY1 or GATA-1 RE mutant p53AIP1 promoter 
construct and p53 or control plasmid, and assayed for β-gal activity. D. All error bars show ± 
























































































































Figure 3.15. Sp1 positively modulates HBx-induced increase in p53AIP1 expression. A. 
Efficient knockdown of Sp1 is achieved using the Sp1-specific siRNA. Shown are western 
blots of Sp1 and loading control GAPDH of THLE-3 cells transfected with the indicated 
siRNAs. B and C. Knockdown of Sp1 using specific siRNAs blunts HBx-induced increase in 
gene expression. B. THLE-3 cells were transfected with Sp1 or control scrambled siRNA. 
P53AIP1 expression was measured using qRT-PCR. C. Hep3B cells were co-transfected with 
wild-type p53AIP1 promoter construct, p53 or control plasmid and Sp1 or control siRNA. 
Cells were transduced with control or HBx recombinant adenovirus 24 h post-transfection 
and assayed for β-gal activity. D. Mutation of Sp1 binding site blunts HBx-induced increase 
in gene expression. Hep3B cells were co-transfected with wild-type or Sp1 RE mutant 
p53AIP1 promoter construct and p53 or control plasmid. Cells were transduced with control 
or HBx recombinant adenovirus 24 h post-transfection and assayed for β-gal activity. All 
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versus control cells, as compared to that in THLE-3 cells. Nevertheless, our findings suggest 
that Sp1 positively modulates p53AIP1 expression in the presence of HBx. Taken together, 
these findings suggest that the p53-associated transcription co-regulators recruited to the 
p53AIP1 regulatory region - YY1 and GATA-1 in the absence of HBx, and Sp1 in the 
presence of HBx – function to modulate p53AIP1 gene transcription.  
 
3.4.2.3 Non-DNA-bound p53 co-regulators 
Next, to identify other potential members of the promoter and intron 1 regulatory 
complexes that do not exhibit sequence-specific DNA binding (termed transcription co-
regulators), a computational approach that assessed associated networks of protein factors 
was employed. Given that each member of a regulatory complex associates with at least one 
other member of the complex (not necessarily p53), all the predicted high confidence 
transcription factors in each region were queried using GeneMANIA association network 
prediction tool.  
 
Strikingly, the most strongly-associated factor predicted at the promoter region was 
histone deacetylase 1 (HDAC1) that associated with three of the five high confidence 
transcription factors namely YY1, GATA-1 and HSF1, in addition to p53 (Figure 3.16A). To 
examine whether HDAC1 is recruited to p53AIP1 promoter region and if this is affected by 
HBx, ChIP was performed on control and HBx THLE-3 cells using an antibody specific for 
HDAC1. The pattern of HDAC1 recruitment strikingly resembled that of p53, YY1 and 
GATA-1 at the p53AIP1 promoter region – HDAC1 was recruited to the promoter region in 
control cells, and this recruitment was markedly reduced in the presence of HBx (p<0.05)  
 
 





























































Figure 3.16. HDAC1 recruitment is perturbed by HBx. A. HDAC1 is predicted to 
associate with p53, YY1 and GATA1. Associated co-regulators adjacent to the promoter p53 
RE was predicted using GeneMANIA. TRANSFAC and MatInspector predicted transcription 
factors are represented by solid grey circles, other associated factors predicted by 
GeneMANIA are represented by white circles. Solid lines linking two circles indicate 
reported association between the two factors. B. Recruitment of HDAC1 to the promoter 
region of p53AIP1 is abolished by HBx. HDAC1 ChIP-qPCR was performed on control and 
HBx THLE-3 cells. ChIP using normal IgG was performed as a non-specific control. All 
error bars show ± SEM of triplicate experiments.  
A 
B 
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(Figure 3.16B). No significant ChIP enrichment at the intron 1 region was detected in both 
control and HBx cells. This suggests that a huge transcriptionally repressive complex of 
transcription factors and co-regulator(s) is recruited to the p53AIP1 promoter region in the 
absence of HBx that negatively regulates p53AIP1 expression. No factors were predicted to 
be strongly-associated with the high confidence transcription factors at the intron 1 region. 
Taken together, our results indicate that HBx abolishes the binding of a p53-containing 
repressive transcription complex at the promoter region and favours the recruitment of a 
transcriptionally activating p53-Sp1 complex at the intron 1 region of p53AIP1, plausibly 
resulting in increased p53AIP1 gene expression. 
 
3.4.3 Expression of transcription co-regulators is generally unaffected by HBx  
 Since our findings thus far demonstrate that p53-associated transcription factors and 
co-regulator(s) are differentially recruited to the p53AIP1 regulatory region in the presence of 
HBx, we asked if this was due to alterations in their expression levels in the presence of the 
viral X protein. We postulated that enhanced degradation or stabilization of the transcription 
factors and co-regulator(s) would affect their availability and thus recruitment to the 
respective response elements.  
 
To test this hypothesis, protein expression levels of transcription repressors YY1, 
GATA-1 and HDAC1 as well as transcription activator Sp1 were examined in control and 
HBx THLE-3 cells using immunoblotting with the respective specific antibodies. As shown 
in Figure 3.17, YY1, GATA-1 and HDAC1 protein levels were found to be comparable in the 
presence or absence of HBx, demonstrating that HBx does not alter their expression. Only 
moderately higher Sp1 expression was detected in HBx cells compared to control cells.  


















Figure 3.17. Expression of transcription co-regulators in the presence of HBx. Western 
blot analysis of YY1, GATA-1 and HDAC1 expression levels using specific antibodies in 
control (C) and HBx (H) THLE-3 cells. GAPDH was used as a loading control.  
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It is possible that increased Sp1 expression may contribute to the enhanced recruitment of the 
transcription activator to its response element observed in our study. However, since the 
protein expression levels of the majority of the transcription factors and co-regulator(s) 
involved are largely unchanged by HBx, this is unlikely to represent the main mode of action 
of the viral X protein. We therefore proceeded to explore other possible mechanisms of 
action of the viral protein in modulating the recruitment of p53-associated transcription 
factors/co-regulators.   
 
3.4.4 Chromatin structure of p53AIP1 regulatory region is not affected by HBx 
We have shown in this study that HDAC1 is recruited together with transcription co-
repressors to the promoter region of p53AIP1 and that this recruitment is abolished in the 
presence of HBx. HDAC1 has been reported to deacetylate lysine (Lys) residues at the N-
terminal tails of histones that is associated with a condensed chromatin state favouring 
transcription repression (Koike, 2009). To investigate if HDAC1 deacetylates histones at the 
promoter region of p53AIP1 following recruitment to this region in the absence of HBx, ChIP 
assay was performed using antibodies specific for acetylated H3 and acetylated H4 on control 
and HBx THLE-3 cells. qPCR analysis of ChIP-enriched p53AIP1 promoter region revealed 
no significant difference in H3/H4 acetylation in the presence or absence of HBx (Figure 
3.18). Since the histone acetylation patterns at the p53AIP1 promoter are unaffected by HBx, 
this suggests that HBx is unlikely to alter chromatin organization at the p53AIP1 regulatory 
region.  
 


























































































Figure 3.18. Acetylation of histones H3 and H4 at p53AIP1 promoter region is not 
altered by HBx. ChIP using antibodies specific for acetylated H3 and acetylated H4 was 
performed on control and HBx THLE-3 cells. ChIP enrichment was measured using qPCR 
with primers specific for p53AIP1 promoter region. 
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To further examine if the chromatin state of p53AIP1 regulatory region is indeed not 
altered by HBx, DNA methylation profiles that is associated with a repressed chromatin state 
were analyzed using methylated DNA immunoprecipitation coupled with microarray 
(MeDIP-chip) of control and HBx THLE-3 cells. Notably, analysis of the DNA methylation 
profiles of the p53AIP1 promoter and intron 1 regions of control and HBx THLE-3 cells did 
not show any significantly differentially methylated sites at both regions (Figure 3.19). 
Collectively, these findings suggest that the differential recruitment of p53-associated 
transcriptional complexes at the p53AIP1 promoter and intron 1 regions are not a result of 
changes in chromatin states of these regions. 
 
3.4.5 HBx enhances p53 site-specific acetylation at lysine 320 that is important for HBx-
deregulated p53AIP1 expression 
In addition to deacetylating histones, HDAC1 also functions to deacetylate non-histone 
proteins such as p53 (Kew, 2011). Luo et al. showed that deacetylation of p53 by HDAC1 
repressed p53-dependent transcription activation. We thus investigated if the promoter-
recruited HDAC1 deacetylates p53 and if the relief in HDAC1 recruitment by HBx restores 
p53 acetylation. To this end, site-specific acetylation of p53 Lys residues was examined in 
control and HBx THLE-3 cells. Of the four p53 Lys residues known to be deacetylated by 
HDAC1 at positions 120 (Mellert et al., 2011), 320, 373 and 382 (Ito et al., 2002), the latter 
three residues for which site-specific antibodies were commercially available were tested. 
Strikingly, acetylation of p53 Lys320 was markedly enhanced in the presence of HBx, while 
that of residues Lys373 and Lys382 remained unchanged (Figure 3.20A). Since p53 Lys320 
is differentially acetylated in control and HBx cells, and as acetylation of p53 can alter its  


























Figure 3.19. DNA methylation profiles of p53AIP1 promoter and intron 1 regions. MeDIP analysis of p53 response element-containing 
promoter and intron 1 regions of p53AIP1 in control and HBx THLE-3 cells. Uppermost panel shows the relative position of the p53AIP1 
transcript; bottom panel indicates the chromosomal position on chromosome 11. Each vertical line in control or HBx panel represents a probe; 
red represents a methylation signal, blue represents a demthylation signal. 
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site-specific DNA binding, we hypothesized that HBx might modulate p53-DNA binding 
through altering p53 Lys320 acetylation.  
 
To examine the sequence-specific DNA binding pattern of acetylated p53 Lys320, 
ChIP was performed on control and HBx THLE-3 cells using an antibody that is specific for 
acetylated p53 Lys320. Intriguingly, binding of acetylated p53 Lys320 to the more conserved 
intron 1 p53 response element of p53AIP1 was enhanced in the presence of HBx (p<0.05) 
(Figure 3.20B). No significant binding of p53 Lys320 to the less conserved promoter p53 
response element was detected (Figure 3.20B). Next, to determine if this site-specific 
acetylation of p53 at Lys320 was essential for p53-mediated deregulation of p53AIP1 by 
HBx, wild-type p53, p53 K320Q acetyl-mimic or non-acetylatable p53 Lys320 (K320R) 
mutant as well as recombinant HBx or control vectors were introduced into p53-deficient 
Hep3B cells, and examined for p53AIP1 expression. Significantly, HBx increased p53AIP1 
expression only in cells with wild-type p53 or the constitutively acetylated K320Q mutant 
(Figure 3.20C). In contrast, comparable p53AIP1 expression levels were detected in control 
and HBx cells with the non-acetylated K320R mutant (Figure 3.20C), suggesting that 
acetylation of p53 Lys320 is necessary for p53AIP1 deregulation by HBx. Taken together, 
these findings strongly implicate p53 Lys320 site-specific acetylation in the modulation of 
p53 sequence-specific DNA binding by HBx.  
 
















































Figure 3.20. Enhanced p53 Lys320 acetylation by HBx. A. Western blot analysis of p53 Lys 320, 373 and 382 acetylation levels in control 
and HBx THLE-3 cells was performed using site-specific antibodies. B. Acetylated-p53 Lys320 is recruited to p53AIP1 intron 1 RE in the 
presence of HBx. ChIP-qPCR was performed on control and HBx THLE-3 cells using Ac-p53 Lys320-specific antibody. ChIP using normal IgG 
was performed as a non-specific control. C. p53 Lys320 acetylation is essential for HBx-induced p53AIP1 expression. Wild-type, constitutively 
acetylated (K320Q) or non-acetylated (K320R) p53 Lys320 was transfected into Hep3B cells and transduced with HBx or control adenovirus 24 
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3.4.6 HBx-enhanced p53 Lys320 acetylation is mediated by PCAF 
To investigate if HBx enhances p53 Lys320 acetylation by relieving HDAC1, 
acetylation levels of p53 Lys320 were examined following depletion of HDAC1 using 
specific siRNA. As shown in Figure 3.21A, acetylated p53 Lys320 levels were comparable 
between control and HDAC1-knockdown cells, indicating that the relief of lysine deacetylase 
activity by HDAC1 depletion is not sufficient for spontaneous acetylation of p53 Lys320 in 
the absence of HBx. Since lysine acetylation is the result of the balance of deacetylase 
(HDAC) and acetyltransferase (HAT) activities, the findings here suggest that lysine 
acetyltransferase(s) may be required to promote p53 Lys320 acetylation in the presence of 
HBx.  
 
 Interestingly, as only site-specific acetylation of p53 at Lys320 was enhanced in the 
presence of HBx, and since the lysine acetyltransferase p300/CBP-associated factor PCAF is 
known to selectively acetylate p53 Lys320 (Liu et al., 1999; Sakaguchi et al., 1998a), we 
hypothesized that PCAF may mediate HBx-induced p53 Lys320 acetylation and subsequent 
p53AIP1 deregulation. To this end, we first examined if PCAF is recruited to the regulatory 
region of p53AIP1. ChIP was performed on control and HBx THLE-3 cells using a PCAF-
specific antibody. Similar to the recruitment pattern of acetylated p53 Lys320, recruitment of 
PCAF to the intron 1 region was enhanced in the presence of HBx (p<0.01) (Figure 3.21B). 
No significant enrichment of the promoter region was detected in control and HBx cells. 
Next, we investigated the possible role of PCAF in mediating the observed HBx-induced 
increase in p53 Lys320 acetylation and p53AIP1 gene expression. To this end, THLE-3 cells 
were treated with PCAF-specific or control siRNA and control or HBx vectors, and examined 
for p53 Lys320 acetylation and p53AIP1 gene expression using immunoblot and RT-qPCR 
analysis respectively. As shown in Figure 3.21C, efficient knockdown of PCAF expression 
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was achieved using PCAF-specific siRNA as compared to that of control siRNA. 
Significantly, PCAF depletion using PCAF-specific siRNA abrogated the HBx-induced 
increase in p53AIP1 gene expression (Figure 3.21C). Concomitantly, a reduction in PCAF 
expression blunted acetylation of p53 Lys320 in HBx cells (Figure 3.21C). Taken together, 
the data strongly suggest that PCAF may play a key role in mediating HBx-induced increase 
in p53 Lys320 acetylation and consequent p53AIP1 gene deregulation. 
 
3.5 Genome-wide p53 chromatin immunoprecipitation-sequencing study reveals unique 
p53-DNA binding characteristics in the presence of HBx 
3.5.1 p53 motif selectivity is altered by HBx  
From the detailed characterization of p53-mediated p53AIP1 deregulation by HBx, 
our findings so far suggest that HBx modulates p53-DNA binding at least in part by altering 
specific post-translational modification(s). This plausibly results in a conformational change 
in the tumour suppressor protein that now preferentially binds to a more conserved consensus 
sequence. Further, in co-operation with adjacent transcription factors and co-regulators, p53 
mediates HBx-induced gene deregulation.  
 
To investigate if this observation represents a general mechanism of p53 modulation 
by the viral X protein, genome-wide p53 chromatin immunoprecipitation coupled with 
sequencing (ChIP-Seq) was performed on THLE-3 cells transduced with recombinant HBx or 
control adenoviral vectors (Figure 3.22A). ChIP-Seq was employed to overcome the main 
limitations of our initial ChIP-on-chip study that only examined a 1.5 kb promoter region of 
genes and was restricted by probe design and coverage. This was particularly important so as 







































































































Figure 3.21. PCAF mediates HBx-induced p53Lys320 acetylation. A. Depletion of HDAC1 does not affect acetylation of p53 Lys320. 
THLE-3 cells were transfected with HDAC1-specific or control siRNA and examined for Ac-p53(Lys320) expression. Shown are the 
immunoblots of HDAC1, Ac-p53 Lys320 and GAPDH (loading control). B. PCAF is recruited to p53AIP1 intron 1 RE in the presence of HBx. 
ChIP-qPCR was performed on control and HBx THLE-3 cells using PCAF-specific antibody. ChIP using normal IgG was performed as a non-
specific control. C. Depletion of PCAF blunts p53 Lys320 acetylation and p53AIP1 upregulation by HBx. THLE-3 cells were transfected with 
PCAF-specific or control siRNA, and transduced with HBx or control vectors 24 h post-transfection. Ac-p53(Lys320) levels were determined 
using western blot analysis while p53AIP1 expression levels were measured by qRT-PCR. All error bars show ± SEM of triplicate experiments. 
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to obtain a truly genome-wide HBx-modulated p53 binding profile to investigate in - an 
unbiased manner - the general mechanism of p53 modulation by HBx.To identify candidate 
p53 binding sites (termed peaks) in control and HBx samples, the peak finder Control-based 
ChIP-Seq Analysis Tools (CCAT) (Tsai and Chung, 2010) was employed and candidate 
peaks were then queried for the presence of the p53 motif using p53scan. As shown in Figure 
3.22B, 426 unique candidate p53 binding sites were identified in control cells while 343 
unique candidate p53 binding sites were identified in HBx cells. To experimentally validate 
these candidate p53 binding sites identified in the control and HBx p53-ChIP samples, 10 
candidate p53 binding sites each from the list of control and HBx were randomly selected and 
validated using p53 ChIP-qPCR performed on control and HBx THLE-3 cells (Appendix). 
Majority (approximately 80%) of these control and HBx candidate p53 binding sites were 
successfully validated by p53 ChIP-qPCR (Appendix A and B), demonstrating that the p53 
ChIP-Seq data is reliable.  
 
We therefore proceeded to examine the nature of the p53 motif(s) in control and HBx 
samples. To this end, the position weight matrices (PWM) of control and HBx p53 motifs 
were obtained. A comparison of PWMs of control and HBx p53 motifs showed that p53 
motifs in the control sample exhibited greater degeneracy in the core nucleotides C, A, T and 
G at positions 4 ,5, 6 and 7 respectively than that in the HBx sample (Figure 3.22C). In 
contrast, the p53 motif in the HBx sample was highly conserved particularly at the core 
nucleotides C, A, T and G at positions 4 to 7 (first half-site) and 14 to 17 (second half-site) 
(Figure 3.22C). This difference in p53 motif degeneracy observed in control and HBx 
samples is especially important since the core nucleotides CATG are critical for interaction 
with the p53 protein as determined by X-ray crystallography studies (Tang et al., 2006a). 
Another difference observed between control and HBx p53 motifs is that the highly 
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conserved p53 motif in the HBx sample consists of two half-sites in tandem, devoid of a 
spacer sequence while that of the control sample consists only of one half-site, indicating 
possible tolerance of variable spacer lengths (Figure 3.22C). This is also particularly 
significant as spacer sequences and lengths between the two half-sites have been reported to 
affect the binding affinity of the p53 protein, possibly contributing to the observed 
modulation of p53-DNA binding by HBx (O'Connor et al., 1995; Sykes et al., 2006). Taken 
together, the global p53 binding patterns observed in control and HBx THLE-3 cells showed 
a preference for a more conserved p53 motif in the presence of HBx. Notably, this is 
consistent with our finding that p53 preferentially bound to a more conserved response 
element at intron 1 of p53AIP1 in the presence of HBx, indicating that the HBx-induced 
change in p53 binding site selectivity at least in part by p53 Lys320 acetylation may represent 
a global phenomenon.  
 
3.5.2 Distinct transcription factors are co-associated with p53 in the presence of HBx 
Since our findings on the deregulation of p53-mediated regulation of p53AIP1 by 
HBx advocate that unique p53-associated transcription factors are favoured in the presence of 
HBx, we therefore investigated if distinct surrounding sequence-specific transcription factors 
are enriched at the candidate p53 binding sites from the genome-wide p53 ChIP-Seq study. 
This analysis was feasible with the use of the p53 ChIP-Seq data as it captured more p53 
binding sites as compared to that of the p53 ChIP-on-chip study that had identified too few 
p53 binding sites for analysis by the co-motif scanning program CENTDIST (Anzola, 2004). 
Together with the superior resolution of ChIP-Seq, our p53 ChIP-Seq study was key to 
examining the possible global mechanism of HBx in modulating p53 sequence-specific DNA 
binding.  
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Figure 3.22. Genome-wide p53 ChIP-Seq study reveals differential p53 motif selectivity 
in the presence of HBx. A. A representative set of control- and HBx-transduced THLE-3 
cells. Approximately 90% transduction efficiency of recombinant HBx and control 
adenovirus (bearing enhanced green fluorescence gene) was consistently achieved in THLE-3 
cells. B. Graphical representation of the number of candidate p53 binding sites identified in 
control and HBx cells using CCAT peak finder tool. C. Different p53 motifs are enriched in 
control and HBx cells. Shown are the position weight matrix logos of the p53 motifs 
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To this end, control and HBx candidate p53 binding sites were first queried for 
proximal co-enriched transcription factor motifs using the co-motif scanning program 
CENTDIST. Differentially co-enriched transcription factor motifs in HBx versus control 
candidate p53 binding regions were then predicted using MotifDiff (unpublished). Table 3.1 
shows the transcription factors that are predicted to be significantly co-associated with p53 in 
the presence of HBx (but not in control cells). Notably, motifs of transcription factors that are 
known to interact with both HBx and p53 were predicted by CENTDIST/MotifDiff to be co-
associated with p53 at candidate p53 binding sites in the presence of HBx, indicating that our 
analysis and findings are relevant in vitro. An example is the transcription factor E2F1 that 
was the third most co-enriched factor (Table 3.1). Additionally, motifs of known p53-
interacting transcription factors such as Sp1 and AP2 were also predicted by 
CENTDIST/MotifDiff to be enriched (Table 3.2). Significantly, the transcription regulator 
Sp1 that we have shown in this work to be preferentially associated with p53 at the p53AIP1 
regulatory region in the presence of HBx was the second most highly co-associated 
transcription factor in the presence of HBx (Table3.1). Taken together, these data support our 
findings that HBx favours distinct transcription co-regulator-p53 associations (or co-
regulatory modules) including Sp1 globally. 
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1 EBOX V$LMO2COM_01 1.55 0.64
2 SP1 V$GC_01 1.51 0.65
3 E2F V$E2F1_Q6_01 1.51 0.66
4 GLI V$ZIC3_01 1.50 0.66
5 EGR V$KROX_Q6 1.45 0.68
6 MYB V$CMYB_01 1.45 0.68
7 CAP V$CAP_01 1.42 0.70





10 ZF5 V$ZF5_01 1.38 0.72
Table 3.1 List of transcription factors that significantly co-associate with 
p53 in HBx sample. 
 
Differentially co-enriched transcription factor motifs in candidate p53 binding sites in HBx 
THLE-3 cells were predicted using MotifDiff. Shown are the rank, transcription family and 
motif, PWM logo of the motif and scores obtained in HBx and control samples of the top 10 
co-enriched motifs. A score greater than 1.3 indicates co-enrichment.  
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Chapter 4 Discussion 
4.1 Basis of this thesis 
 The hepatitis B virus X protein, HBx is strongly implicated in hepatitis B virus 
associated hepatocellular carcinoma. A major way by which HBx promotes 
hepatocarcinogenesis is through its function as a transcription co-factor. It is widely accepted 
that HBx does not possess sequence-specific DNA binding properties, but instead perturbs 
cellular gene expression program by interacting with and modulating a variety of host 
transcription regulators. As transcription regulators are a vital component of the cellular 
apparatus that carefully orchestrates the gene expression program to maintain cellular 
homeostasis, disrupting the integrity of transcription regulation therefore has potentially 
detrimental consequences in tumourigenesis and tumour progression (Woo et al., 2011). It is 
thus pertinent to understand the transcription co-factor role of the viral X protein in 
contributing to hepatocarcinogenesis. 
 
 To study the transcription co-factor function of HBx, we chose to examine its 
modulatory effect on a known HBx-interacting transcription factor p53. P53 was carefully 
selected for the following reasons: firstly, the tumour suppressor protein p53 is regarded as a 
master regulator of transcription that controls key cellular processes such as cell cycle, DNA 
repair, apoptosis and senescence and is thus particularly biologically relevant. Although more 
than 60% of cancers have been reported to possess mutated or inactivated p53, p53 mutations 
in the early stages of HCC are infrequent (Feitelson et al., 1993). Secondly, albeit limited 
literature reports in this field, modulation of p53 by HBx is the most studied among the 
known HBx-interacting transcription factors. Moreover, the availability of a relatively large 
body of knowledge on general p53 transcription regulation would serve to facilitate our study 
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on the deregulation of p53 transcription by the viral X protein. For these biologically 
pertinent and practical reasons, the tumour suppressor protein p53 was selected for studying 
the transcription co-factor function of HBx in hepatocarcinogenesis. 
 
4.2 Importance of altered p53-mediated regulation by HBx  
The literature to date has provided some clues on how HBx modulates p53. Firstly, 
we and several independent groups have established that HBx interacts with p53 and co-
localize in the nucleus. Secondly, unlike the human papillomavirus E6 oncoprotein and the 
Epstein-Barr virus nuclear antigen 3C that disrupt p53 function by enhancing p53 
ubiquitination and proteasomal degradation (Scheffner et al., 1993; Scheffner et al., 1990), 
we and others have shown that HBx does not affect p53 expression levels (Chung et al., 
2003; Lee et al., 2005a). Consistently, we have also demonstrated in this work that p53 
expression is comparable in the presence or absence of HBx, and that a large fraction of p53 
is localized to the nucleus. How then does HBx modulate p53? The first clues to this question 
came from a few early in vitro binding assays that showed changes in p53-DNA binding in 
the presence of HBx, although the changes reported were seemingly contradictory: HBx 
inhibited p53-DNA binding in some studies (Chung et al., 2003; Elmore et al., 1997), but 
potentiated p53-DNA binding in another study (Truant et al., 1995a). This discrepancy in 
findings was thought to be partly attributed to the different in vitro systems in which the 
effect of HBx was examined. Nevertheless, subsequent work by Chung et al. significantly 
highlighted the potential biological consequences of such a modulation: abrogation of p53-
DNA binding at the promoter of the tumour suppressor PTEN by HBx was linked to its 
deregulated expression (Chung et al., 2003). However, the lack of progress made in this area 
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thereafter continued to present a huge gap in knowledge of the transcription co-factor role 
and the mechanism of action of the viral X protein.  
 
 To address this, we employed a global integrative approach to obtain an overall view 
of HBx-altered p53 DNA-binding patterns that are associated with corresponding aberrant 
gene expression. Using a HBx-expressing cell culture system, we employed two powerful 
tools: (i) chromatin immunoprecipitation coupled with microarray (ChIP-on-chip) to identify 
global differential p53-DNA binding patterns in the context of the chromatin and cellular 
milieu and, (ii) microarray expression profiling to identify genes deregulated by HBx. This is 
the first report that shows the global effect of HBx on p53 sequence-specific DNA binding. 
We found that HBx can potentiate, relieve as well as shift p53 DNA-binding and that these 
alterations were associated with deregulated corresponding gene expression. This finding 
suggests that HBx can indeed alter biologically functional p53-DNA binding characteristics 
in opposing manners, suggesting that the seemingly contradicting reports of HBx on p53-
DNA binding were likely to have been real observations and were not mere artefacts of 
different in vitro systems. A model previously proposed purported that HBx repressed gene 
transcription through a repressive domain that contacts the basal transcription machinery 
(Truant et al., 1995a). However, the findings in this thesis suggest that the deregulation of 
p53-mediated transcription is far more complex than that. This is evidenced by the 
observation that HBx-altered p53-DNA binding was linked to transcriptional activation of 
some genes and transcriptional repression of other genes. The complexity of transcription 
deregulation by HBx is highlighted by the finding that the various HBx-induced p53-DNA 
binding alterations (enhancement, abolishment or a shift) did not associate with any specific 
type of gene deregulation pattern (stimulation or inhibition). This suggests that a more 
intricate, multifaceted interplay of virus-host interactions is at work. Instead, our findings 
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suggest that the viral X protein may deregulate p53-mediated transcription through a more 
complex mechanism that possibly involves other transcription factors and/or co-regulators. 
 
 To gain a better understanding of the modulation of p53 sequence-specific DNA 
binding property by HBx, we characterized a HBx-deregulated p53-regulated candidate gene 
that was identified from our global study - p53AIP1. P53AIP1 was deemed as an attractive 
candidate for further characterization studies for several reasons. First, as its name suggests, 
p53AIP1 is a known p53-regulated gene. Secondly, its function in promoting apoptosis – the 
most ancestral function of p53 - has been characterized and the observed HBx-deregulated 
increased p53AIP1 expression from microarray expressing profiling is consistent with the 
apoptosis-inducing role of HBx.  
 
 Our findings here provide strong evidence that HBx disrupts p53-mediated 
transcription regulation by modulating p53 recruitment to its regulatory elements. Using 
p53AIP1 as a model, we have successfully showed that HBx induced a novel shift in p53 
recruitment from the promoter to intron 1 region of p53AIP1 and that this directly resulted in 
a deregulated increase in expression. This finding is significant in several ways: this is the 
first evidence demonstrating that HBx can alter p53 selectivity for distinct binding sites 
within the regulatory region of a particular gene. Importantly, this change in p53 selectivity 
induced by the viral X protein has serious biological consequences – that of aberrant gene 
expression. This is potentially detrimental to the cell since p53 regulates important cellular 
processes by the co-ordinated transcription regulation of critical genes. Modulation of p53-
mediated transcription by the viral X protein would thus conceivably upset the delicate 
balance of cellular homeostasis. This is particularly pertinent in an environment of chronic 
Chapter 4 Discussion 
108 
 
inflammation and constant liver injury and regeneration such as that in hepatitis and liver 
cirrhosis. HBx-altered p53 function might impair the cell’s physiological response to these 
stresses and predispose hepatocytes to neoplastic transformation. 
 
Indeed, the findings in this thesis allude to the adverse biological consequences of 
deregulated p53 regulation by the viral X protein. Specifically, we found that the enhanced 
expression of p53AIP1 in the presence of HBx plays a key role in tipping the balance in 
favour of cellular apoptosis. This is consistent with the increasing amount of evidence that 
points to the pro-apoptotic function of the viral X protein. In this work, we have also found 
that pro-apoptotic p53AIP1 expression is significantly elevated in HCC patients with high 
expression of the hepatitis B virus X protein. At first glance, the pro-apoptotic function of 
HBx appears to be incompatible with its role in neoplastic transformation and 
hepatocarcinogenesis, a hallmark of which is the cell’s resistance to apoptosis. How then do 
we reconcile the apoptotic-promoting effect of the viral X protein with its role in 
hepatocarcinogenesis? A possible explanation may lie in the way normal tissue homeostasis 
is maintained by a delicate balance between cell growth and apoptosis. In the event of cell 
stress or injury such as during viral infection, apoptotic cells release mitogenic factors that 
stimulate proliferation of neighbouring cells – a process termed ‘apoptosis-induced 
compensatory proliferation’ (Ryoo et al., 2004). Accordingly, induction of apoptosis by the 
viral X protein may consequently enhance compensatory proliferation and promote 
regeneration of hepatocytes. Such a cellular environment may exert a selective pressure for 
premalignant hepatocytes that are resistant to apoptosis, a precursor to hepatocarcinogenesis.  
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4.3 A novel mechanism of the HBx transcription co-factor 
In dissecting the molecular mechanism by which the viral X protein altered p53 
sequence-specific DNA binding characteristics and consequence p53-regulated transcription, 
our findings strongly suggest that HBx alters the recruitment of distinct transcription factors 
and co-regulators(s) to the regulatory region of p53AIP1 and that these transcription 
complexes consequently modulate p53AIP1 expression. This was founded on the knowledge 
that mammalian transcription regulation generally involves the co-ordinated action of 
multiple transcription factors and chromatin modifiers. Furthermore, a variety of transcription 
factors have been reported to mediate the indirect binding of the viral X protein to DNA, 
suggestive of possible multi-protein transcription complexes that are involved.  
 
Using the power of bioinformatics predictions and chromatin immunoprecipitation 
assays to identify transcription co-regulators that are directly as well as indirectly bound to 
the p53AIP1 regulatory region, our findings strongly suggest that p53 functions together with 
other transcription co-regulators in a multi-protein complex at the p53AIP1 regulatory region. 
Our findings suggest that specific combinations of p53 and proximal sequence-specific 
transcription factors together recruit distinct non-DNA-bound transcription regulators such as 
HATs and HDACs. In addition to modulating gene transcription, we found that the HATs and 
HDACs in turn modify specific p53 acetylation patterns, altering p53 selectivity for its 
binding sites. Intriguingly, we found that the viral X protein alters p53 transcription 
regulation by perturbing the recruitment of unique p53-transcription co-factor combinations 
and thus the non-DNA-bound transcription regulators that are recruited to the regulatory 
regions of genes. Using p53AIP1 as a model, we showed that HBx disrupted a 
transcriptionally repressive p53-YY1-GATA-1-HDAC1 complex at the p53AIP1 promoter 
that served to keep p53AIP1 expression under tight control. Instead, HBx favoured 
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recruitment of p53 with the co-activator Sp1 at the intron 1 region that further recruited the 
transcription co-activator PCAF in a transcriptionally stimulating complex.  
 
To further delineate the mechanism by which HBx perturbs the recruitment of the 
distinct transcription complexes, we explored several hypotheses. Firstly, we hypothesized 
that the observed modulated patterns of p53-DNA binding might be a consequence of altered 
transcription factor/co-regulator protein levels and thus their availability for recruitment in 
HBx-expressing cells. However, our findings suggest that the protein expression levels of the 
transcription factors/co-regulators examined were generally unaffected by the viral X protein, 
effectively ruling out this possibility.  
 
Secondly, we hypothesized that the modulated p53-DNA binding patterns may be the 
result of HBx-induced global changes in chromatin structure and accessibility. Chromatin 
structure can be altered by various modifications such as DNA methylation and covalent 
modifications of histone tails. Here, we show that comparable DNA methylation profiles of 
the p53AIP1 regulatory region were detected in the presence or absence of HBx. Moreover, 
we demonstrate that HDAC1-regulated histone acetylation patterns at the p53AIP1 promoter 
region were also unaffected by HBx, suggesting that the differential p53-DNA binding 
patterns observed in the presence of HBx are unlikely a result of a change in gross chromatin 
structure but through other mechanisms. 
 
 Next, since the HBx-altered recruitment of transcription co-regulators HDAC1 and 
PCAF regulate acetylation of non-histone proteins such as p53, and as post-translational 
modification of p53 is associated with altered sequence-specific DNA binding, we 
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hypothesized that HBx might alter p53 binding site selection by affecting its acetylation 
pattern via perturbing the HDAC1-PCAF balance. Indeed, our findings suggest that tipping of 
the HDAC-HAT balance by HBx activated a PCAF-specific p53 Lys320 ‘acetylation switch’ 
that is in part responsible for conferring p53 binding site selectivity for more conserved p53 
response elements. Based on these findings, we postulate that under normal conditions, 
HDAC1-deacetylated p53 Lys320 preferably binds to the less conserved p53 response 
element, locking the transcriptionally repressive p53-YY1-GATA-1-HDAC1 complex at the 
p53AIP1 promoter, thus preventing aberrant transcription of the pro-apoptotic gene (Figure 
4.1). This mode of transcription inhibition is conceivably advantageous to the cell as it 
safeguards the cell against undergoing aberrant apoptosis under normal conditions, and is 
‘primed’ to activate p53AIP1 transcription in response to genotoxic stress through the rapid 
disassembly and re-assembly of desired transcription regulators on an ‘open’ chromatin. In 
fact, upon cellular stress by the expression of the viral X protein, HBx instead favours 
recruitment of a p53-Sp1 transcription co-activator combination that engages PCAF, which 
steers p53 to a more conserved response element at the p53AIP1 intron 1 region by activating 
a p53 Lys320 ‘acetylation switch’. We postulate that enhanced acetylation of p53 Lys320 
induces a conformational change in the p53 protein that now preferably binds more 
conserved p53 response elements. Consequently, this HBx-induced shift in transcription 
regulator recruitment from a repressor to an activator complex aberrantly stimulates p53AIP1 
expression that directs the cell towards apoptosis.  
 






















Figure 4.1 Model of p53-mediated p53AIP1 deregulation by HBx. In unstressed cells, a 
repressive p53-YY1-GATA-1-HDAC1 transcription complex occupies the promoter of 
p53AIP1, keeping gene transcription under tight control. Upon HBV infection and the 
selective over-expression of HBx, HBx enhances PCAF-mediated acetylation of p53Lys320 
and induces a conformational change in p53 that favours binding to a stronger consensus 
sequence in intron 1. Together with the transcription activator Sp1, the HBx-PCAF-p53-Sp1 
complex is recruited to the intron 1 region of p53AIP1, resulting in aberrant stimulation of its 
gene expression. 
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Several lines of evidence further indicate that our proposed model of deregulated p53-
mediated transcription may represent a global mechanism of the viral X protein. Firstly, 
distinct transcription factor motifs - including that of Sp1 - were found to be selectively co-
enriched in the vicinity of the p53 binding sites in the presence of HBx from the global p53 
ChIP study. In addition, many of these transcription co-factors motifs were also significantly 
enriched in HBx direct target genes from a global HBx ChIP study that was previously 
conducted in our lab (Sung et al., 2009). Many of these transcription co-factors have also 
been reported to interact and co-operate with p53 in regulating cell growth and/or apoptosis 
such as E2F1 (O'Connor et al., 1995), GLI (Brandner, 2010), c-myb (Sala et al., 1996), and 
AP2 (McPherson et al., 2002; Mertens et al., 2002). Collectively, this suggests that specific 
p53-transcription co-regulator combinations are globally favoured by the viral X protein. 
Secondly, p53 universally bound to more conserved response elements in the presence of 
HBx. This was revealed by a comparison of the structural characteristics of the p53 DNA 
consensus sequence of p53 binding sites in the presence and absence of HBx from the global 
p53 ChIP study. We postulate that specific post-translational modifications of the p53 protein 
such as enhanced p53 Lys320 acetylation as a result of altered transcription regulator 
recruitment may be responsible for the altered preference for more conserved p53 response 
elements. Taken together, these findings from global ChIP studies strongly suggest that the 
mechanism of p53-mediated deregulation the viral X protein illustrated by the p53AIP1 
model may represent a global mechanism by which HBx deregulates cellular transcription.  
 
The finding that HBx perturbs acetylation of p53 only at specific Lys residue(s) is 
particularly fascinating. HBx enhanced PCAF-mediated acetylation of p53 Lys320 but did 
not affect p300/CBP-associated acetylation of p53 Lys373 and Lys382. Additionally, our 
findings suggest that selective engagement of the acetyltransferase PCAF is critical to the 
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differential acetylation patterns observed since removal of p53 deacetylation by HDAC1 did 
not lead to a spontaneous increase in p53 Lys320 acetylation levels. Taken together, these 
findings allude to the specific hijacking of the PCAF-mediated acetylation system by the viral 
X protein. Interestingly, several other viral proteins such as the adenovirus E1B-55kDa and 
human immunodeficiency virus type-1 Tat proteins have been reported to deregulate p53 
transcription by interfering with the physical interaction of PCAF and p53, thus inhibiting 
PCAF-mediated p53 Lys320 acetylation (Harrod et al., 2003; Liu et al., 2000). It will be of 
importance to investigate the mechanism by which HBx conversely enhances PCAF-
mediated p53 Lys320 acetylation. Additionally, it will be particularly interesting to 
investigate if deregulation of PCAF by HBx represents a mode of general transcription 
deregulation by HBx. Analysis of other transcription factors that are acetylated by PCAF 
such as E2F1 (Martinez-Balbas et al., 2000) – a transcription factor that is co-enriched with 
p53 in the presence of HBx as well as enriched at HBx direct target genes – will provide 
clues to this question. If so, PCAF could present an attractive drug target that is more specific 
as compared to the broad range HDAC inhibitors that are used in cancer treatment.  
 
Additionally, it is possible that HBx may disrupt other factors in addition to PCAF 
that modify the p53 protein post-translationally, thus contributing to an altered ‘post-
translational code’. First, to obtain a more complete understanding of the effect of HBx on 
p53 acetylation, it may be worthwhile to examine the potential effect of HBx on another 
family of acetyltransferases – hMOF and TIPP60 of the MYST family that was recently 
shown to acetylate p53 at Lys120 (Sykes et al., 2006; Tang et al., 2006b). In addition, it is 
possible that HBx may also interfere with other p53 site-specific post-translational 
modifications such as phosphorylation (other than Ser46), ubiquitination, sumoylation, 
neddylation and methylation through the interaction with specific p53 modifying enzymes. 
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We predict that crosstalk between the various p53 site-specific modifications induced by HBx 
may determine modulation of p53 sequence-specific binding characteristics and consequent 
p53 transcription deregulation. 
 
 Going forward, in addition to investigating the role of wild-type HBx on p53 
regulation/site specific binding, it will be pertinent to examine the role of clinically relevant 
mutant forms of the viral protein on p53 as well. Of particular mention are HBx mutants that 
have been frequently found to be deleted at the 3’-end in HCC tumours (Iavarone et al., 2003; 
Ma et al., 2008; Poussin et al., 1999; Tu et al., 2001; Wei et al., 1995). Several studies have 
reported that carboxy-terminal truncated HBx retain their transactivational activities (Balsano 
et al., 1991; Kumar et al., 1996a). Notably, Kumar et al. demonstrated that a HBx truncated 
mutant (residues 58-140) – that contained intact p53 binding domain – maintained its 
transactivating function (Kumar et al., 1996a). On the contrary, other studies that examined 
larger portions of 3’-end truncated HBx mutants identified from HCC tumours report a lost in 
their transctivational activities, their inhibitory effect on cell proliferation and transformation 
as well as their pro-apoptotic effect (Ma et al., 2008; Tu et al., 2001; Wang et al., 2004; 
Zhang et al., 2008). Hence, it will also be important to dissect the role of these clinically 
relevant HBx mutants on the regulation of p53 as well as on p53-independent pathways that 
may facilitate hepatocarcinogenesis. 
 
4.4 Significance of our work on the field of p53 research 
Investigation of p53 transcription deregulation by the hepatitis B viral X protein not 
only provides new insight on virus-host interactions, but also advances our understanding of 
general p53-mediated transcription regulation.  




Departing from the initial simplistic one transcription factor-one gene model of 
transcription regulation, it is now widely accepted that p53 transcription regulation typically 
involves the intricate interplay of other sequence-specific transcription factors and co-
regulators that modulate p53 target gene expression. Additionally, there is growing support 
for the importance of p53 post-translational modifications in regulating p53 transcription 
activity. Consistently, our work in this thesis provides evidence here that indeed the 
transcription factor p53 does not function in isolation, but rather as ‘p53 cassettes’ – a 
collective term used to describe the combination of p53 modifications and associated 
transcription factors and/or regulators. Additionally, from our study of p53 transcription 
deregulation by the hepatitis B virus X protein, we show that in response to stress, distinct 
p53 cassettes are recruited to specific regulatory regions of selected target genes that co-
ordinate their expression to elicit an appropriate cellular response. So how are different p53 
cassettes specifically recruited to selected response elements? Characterization of p53-
mediated p53AIP1 deregulation by the viral X protein presented in this thesis provides some 
clues to the regulation of p53-DNA binding selectivity. 
 
Importantly, we found that a specific reversible p53 Lys320 acetylation mark 
determined by the opposing action of HDAC and HAT recruited by distinct p53-transcription 
co-factor combinations confers selectivity for p53 response elements with particular DNA 
structural characteristic. Indeed, there has been growing advocacy for the idea of such an 
acetylation ‘sensor system’. In this theory, distinct HATs/HDACs are activated/recruited in 
response to specific genotoxic stresses and mediate differential acetylation of distinct p53 Lys 
residues. The p53 ‘acetylation code’ thus acts as a sensor by which p53 selectively engages 
classes of p53 target genes that directs the appropriate cell fate. It is speculated that attaching 
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acetyl moieties to the ε-amino group of p53 Lys side chains changes the conformation of the 
p53 protein in such a way that it binds response elements that have specific DNA structural 
characteristics. In support of this, we have found that acetylated p53 Lys320 preferentially 
binds p53 response elements that exhibit greater sequence similarity to the consensus 
sequence. The exact physical mechanism however, remains to be clarified and would 
undoubtedly be facilitated by X-ray crystallography studies of various p53 acetylation 
mutants in complex with DNA. It is also important to note that this theory assumes that each 
class of p53 target genes (eg. cell cycle) is regulated by p53 response elements of similar 
DNA structural characteristics, and that this differs from those in other classes of target genes 
(eg. apoptosis). However, attempts at defining a hard and fast rule for classifying p53 
response elements according to their specific classes of target genes based solely on their 
DNA structural characteristics have shown that it is not so clear cut. Moreover, our findings 
here highlight an additional level of complexity in p53 target gene selectivity. We have 
demonstrated that p53 can differentially bind to distinct response elements that regulate a 
single gene. As an increasing number of p53-regulated genes are found to contain more than 
one (or a cluster of) functional p53 response elements at their regulatory region, we believe 
that it may be more meaningful to further dissect p53 target site specificity instead in the 
context of each p53-regulated gene. 
 
Various studies have reported conflicting roles of site-specific p53 Lys320 acetylation 
in influencing cellular outcome. On the one hand, acetylation of p53 Lys320 has been 
associated with promoting cell survival. Knights et al. demonstrated that acetylation of p53 
Lys320 repressed several pro-apoptotic genes while positively regulating some genes 
involved in cell survival in lung carcinoma cells (Knights et al., 2006). Similarly, using a 
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murine model, Chao et al. showed that non-acetylatable p53 Lys320 mutants resulted in 
stimulation of pro-apoptotic genes and was associated with apoptosis induction in particular 
cell types such as thymocytes, epithelial cells of the small intestine and retinal cells (Chao et 
al., 2006). On the other hand, Terui et al. showed that acetylated p53 Lys320 lead to an up-
regulation of pro-apoptotic genes Pig and Noxa in gastric carcinoma cells (Terui et al., 2003). 
Consistent with the proposed pro-apoptotic function of acetylation p53 Lys320 by Terui et 
al., we found that acetylated p53 Lys320 is important for stimulating p53AIP1 expression. A 
likely explanation for the discrepancy in findings could lie in the different cell types used in 
each study and generalization of p53 regulation mechanisms would be perilous. The specific 
repertoire of proteins and regulatory networks at work in each cell type may exert different 
regulatory effects on the p53 protein that might not have been examined in these studies. 
There is a possibility that recruitment of unique cell type-specific p53 cassettes may mark 
p53 with unique post-translational codes whose crosstalk and/or compensatory functions are 
still being investigated. Additionally, assessing the effect of these post-translational codes in 
various cell types in an in vivo model will provide a more complete understanding of the 
physiological relevance of p53 modifications. Unfortunately, Chao et al. did not examine the 
effect of non-acetylatable p53 Lys320 mutants in liver cells in the murine model used that 
could have provided useful information for our study. Collectively, these studies caution 
against drawing general conclusions about particular p53 modifications without carefully take 
into account the unique landscape of each cell type used. Moreover, this highlights the 
complexity of p53 transcription regulation but may also present exciting possibilities for 
targeted cell-type specific therapy.  
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Our findings strongly suggest that the main function of p53 site-specific acetylation of 
Lys320 is in conferring sequence-specific binding properties and not in affecting p53 
stability. It is suggested that since the same p53 Lys residue can be modified by acetylation 
and ubiquitination, exclusion of ubiquitination by acetylation of the residue prevents 
degradation of p53. However, there are no reports to suggest that p53 is ubiquitinated at 
Lys320 and the only other modification reported at this residue, neddylation, was shown not 
to affect its stability but to inhibit p53 activity (Abida et al., 2007). In support for the role of 
acetylation in altering p53 sequence-specific DNA-binding/activity, knock-in studies of 
carboxy-terminal lysines of the mouse p53 gene showed no effect on p53 stability but 
functioned by fine-tuning p53 activity (Feng et al., 2005).  
 
From our study of how the viral X protein hijacks the p53 transcription machinery in 
this thesis, our findings allude to the great complexity of several inter-linked regulatory 
mechanisms that govern p53-mediated transcription. The importance of regulation by post-
translational modifications of the p53 protein described above is important in so far as in 
influencing p53 binding site selectivity, but the intricacy of p53-mediated gene expression is 
highlighted by the observation that only a subset of all p53-DNA binding events actually 
affects gene transcription. In concordance with this, we show that p53-regulated gene 
transcription is likely the result of the convergence of multiple layers of regulation including, 
but not limited to (i) recruitment of specific combinations of transcription co-factors and co-
regulators, (ii) recruitment of chromatin remodelling factors and, (iii) combinations of p53 
post-translational modifications. Other equally important factors though not examined in this 
thesis such as p53 binding factors, other p53 family members such as p63 and p73 that 
exhibit overlapping functions with p53 as well as the emerging role of p53-responsive 
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microRNAs may also be involved in modulating p53 transcription and ultimately determining 
cellular outcome. These various mechanisms reflect the intricacy of fine-tuning the master 
regulator p53 response to various cellular stresses and also present multiple safeguards 
against breaches by exogenous agents such as viral proteins.  
 
4.5 Conclusion and future perspectives 
Our work presented in this thesis has provided new insights to how the hepatitis B 
virus X protein deregulates p53 transcription regulation and offers clues as to how the virus 
has evolved to hijack the p53 transcription machinery and alter cellular outcome. 
 
We have shown that p53-regulated gene transcription is carefully orchestrated by (but 
not limited to) a dynamic interplay of transcription co-factors and co-regulators as well as 
specific p53 post-translational modifications, and that the viral X protein functions by 
upsetting this system. Using p53AIP1 gene regulation as a model, our findings suggest that 
HBx does this by hijacking the p53 acetylation sensor system through differentially favouring 
the recruitment of unique HDAC- or HAT-containing p53 cassettes. The shift in the HDAC-
HAT balance alters the specific acetylation code of the p53 protein, modulating p53 
sequence-specific DNA-binding selectivity that can result in aberrant corresponding gene 
expression with functional consequences and clinical relevance in hepatocarcinogenesis. 
Based on our findings, we advocate that future efforts be focused on elucidating the specific 
‘p53 cassettes’ – the combination of transcription co-factors and co-regulators as well as p53 
post-translational modifications – that are perturbed by HBx., This effort needs to 
amalgamate a host of information by harnessing the power of chromatin immunoprecipitation 
coupled with massive parallel sequencing: genome-wide HBx and HBx-altered p53 binding 
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profiles, differential recruitment patterns of p53 transcription co-factors and co-regulators, 
HBx-altered histone modification profiles as well as combinations of HBx-altered p53 post-
translational modifications. This must be further integrated with HBx-deregulated gene 
expression profiles to elucidate functional p53 cassettes that are responsible for transcription 
deregulation. Dissecting the intricate interaction of all these factors presents a mammoth task, 
but is one that will undeniably provide a more coherent model of how the viral protein 
deregulates transcription of the cell’s master regulator. 
 
 In the greater scheme of things, we envisage that HBx may similarly deregulate other 
transcription factors that may function either independently or in combination with p53. Co-
ordinated efforts in dissecting the patterns of altered co-regulatory modules by the viral X 
protein will undoubtedly advance our understanding of how such a small viral protein 
perturbs cellular transcription regulation. In addition, future work will also need to analyze 
the mechanism of HBx modulation of these co-regulatory modules in the context of 
chromosomal looping. We would need to examine if HBx perturbs the interaction of 
proximal and distant transcription factors, co-regulators, chromatin modifiers and remodelers 
that were brought together into so called ‘transcription factories’ by chromosomal looping. 
 
 Lastly, these studies should ideally be performed in normal liver cells as well as in 
tumours obtained at various stages of the disease to obtain a more comprehensive 
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Appendix A. ChIP-qPCR validation of 10 randomly selected Control-enriched 
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Appendix B. ChIP-qPCR validation of 10 randomly selected HBx-enriched candidate 
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